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i. introduction
In 2007, the National Institutes of Health (NIH) launched the Human Microbiome 
Project (HMP), a $150 million initiative to characterize the microbial communities 
found at several different sites on the human body and to analyze the role of these 
microbes in human health and disease.2 Many lines of research have demonstrated the 
significant role of the microbiota in human physiology. The microbiota is involved, for 
example, in the healthy development of the immune system, prevention of infection from 
pathogenic or opportunistic microbes, and maintenance of intestinal barrier function. 
Goals of the HMP have been described as “identifying new ways to ‘determine health 
and predisposition to diseases [as well as defining] the parameters needed to design, 
implement and monitor strategies for intentionally manipulating the human microbiota, 
to optimize its performance in the context of an individual’s physiology.’”3 
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is solely the responsibility of the authors and does not necessarily represent the official views of the NHGRI 
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2 See Office of Strategic Coordination, Human Microbiome Project, nat’l inst. of HealtH, http://
commonfund.nih.gov/hmp/ (last visited Feb. 7, 2014). 
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41 J. laW, Med. & etHiCs 454, 455 (2013) (quoting Peter J. Turnbaugh et al., The Human Microbiome Project, 
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As part of the HMP, NIH funded the “Healthy Cohort Study,” an effort to create a 
reference catalogue of microbial DNA in healthy adults4 as well as fifteen demonstration 
projects focusing on bacterial, fungal, and viral changes in microbiomes in individuals 
with various diseases. Early findings of the HMP were published in June 2012.5 While 
the findings are helping us understand the role and variation of microorganisms within 
and across individuals, they are also promoting interest in the development of probiotic 
products.6
Probiotics are substances containing live microorganisms that are thought to have a 
beneficial effect on the human body by manipulating microbiome and host properties.7 
Research has shown that it is possible to categorize the microbiota components on the 
basis of whether they exert potentially pathogenic or health-promoting aspects. For 
example, lactic acid-producing genera such as bifidobacteria or lactobacilli have a 
long-standing association with health. These bacteria can be increased in the human 
body (at least for a period of time) either by feeding individuals appropriate strains 
as a probiotic or through the provision of prebiotic growth substrates. While several 
probiotics are now undergoing preclinical and clinical trials,8 none have as yet been 
approved as drugs in the United States. Probiotics have, however, been available as 
foods and dietary supplements for many years. Initially marketed in yogurts and dairy 
products, the use of probiotics in commercial products has skyrocketed in recent 
years.9 Other probiotic products include juices, nutrition bars, infant formulas, relishes 
and condiments, sweeteners, waters, pizza crust, gum, lozenges, dietary supplements, 
toothpaste, and cosmetics.10 
In addition to funding the Healthy Cohort Study and the demonstration projects, NIH 
set aside a portion of HMP funds to study the ethical, legal, and social implications 
(ELSI) of the HMP’s scientific goals. Among the funded ELSI studies was an effort 
4 See Press Release, NIH Human Microbiome Project Defines Normal Bacterial Makeup of the Body 
(June 13, 1013), http://www.genome.gov/27549144. Subjects contributed samples from multiple body sites 
(skin, mouth, throat, nostrils), feces (to obtain microbial samples from the lower gastrointestinal tract) and 
the vagina, in women. 16S rRNA gene analyses were performed on bacteria from the samples. See David A. 
Relman, Learning About Who We Are, 486 nature 194 (2012).
5 The Human Microbiome Project Consortium, A Framework for Human Microbiome Research, 486 
nature 215 (2012). 
6 See Jeffrey I. Gordon, Honor Thy Gut Symbionts Redux, 336 sCienCe 1251 (2012). With the advent 
of the HMP, research relating to probiotics has increased significantly in the last decade. In terms of clinical 
studies, a search of PubMed conducted in 2013 under the search term “probiotics” revealed no studies prior 
to 1991; 5 studies from 1995 to 1997; 384 from 2007-2009, and 430 from 2010 to 2012. 
7 There is no statutory or regulatory definition of probiotics in the United States. The most widely used 
definition of probiotics is the definition proposed in the report of a Joint FAO/WHO Expert Consultation. 
food & agriC. org. of tHe u.n. & World HealtH org., evaluation of HealtH and nutritional properties 
of probiotiCs in food inCluding poWder Milk WitH live laCtiC aCid baCteria (2001), available at http://
www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf. In that document, probiotics are 
defined as “live microorganisms which when administered in adequate amounts confer a health benefit on 
the host.” Id. at 5.
8 See Bernat Olle, Medicines from Microbiota, 31 nature bioteCHnology 309, 314 tbl.3 (2013).
9 See Functional Foods Lead the Probiotic Market’s Continued Growth, nutraCeutiCals World 
(June 10, 2013), http://www.nutraceuticalsworld.com/contents/view_breaking-news/2013-06-10/functional-
foods-lead-the-probiotic-markets-continued-growth/. See also Ewa Hudson, Challenging Economic Climate 
No Threat to Probiotics, natural produCts insider (Oct. 19, 2012), http://www.naturalproductsinsider.
com/articles/2012/10/challenging-economic-climate-no-threat-to-probiot.aspx; Jeff Gelski, Staking Out 
Probiotic Claims, food bus. neWs (Sept. 30, 2010), http://www.foodbusinessnews.net/News/News%20
Home/Features/2010/9/Staking%20out%20probiotic%20claims.aspx?cck=1.
10 See Commercial Strains Sold as Probiotics, Cal. dairy res. found., http://cdrf.org/home/checkoff-
investments/usprobiotics/products-with-probiotics/#commercial (last visited Jan. 31, 2014).
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to look at the current regulatory framework for probiotics11 and to determine if it is a 
good fit for the range of probiotics that are on the market, under development, or that 
may be developed in the future as a result of the HMP. New claims are being made 
about the role and value of probiotics in promoting human health and well-being, and 
there is both uncertainty and debate about how these products should be regulated.12
As probiotics begin to proliferate in the market, policy makers and regulators need 
to critically consider the regulatory structure that is most appropriate for them. This 
consideration should incorporate the wide range of probiotic products that are and may 
become commercially available as foods, food additives, drugs, dietary supplements, 
and cosmetics, and should anticipate the future types of probiotic products that may 
be developed. Scientists have theorized that, in the future, there may be interest in 
combining probiotics to leverage their different properties, perhaps with personalized 
probiotics for a healthy microbiome. Experts in the field also expect that there will 
be more interest in genetic engineering of probiotics for specific medical purposes as 
more is known about probiotic mechanisms of action. In order to protect and guide 
consumers and health care providers who may use or recommend the use of probiotics, 
a regulatory structure that adequately accounts for the risks of probiotics as well as the 
accuracy of claims of effectiveness is necessary. In addition, the regulatory structure 
needs to be flexible enough to allow for (or at least not discourage) research on new 
probiotic products that may have therapeutic benefits.13 
This article reports on the findings of a Working Group (WG) consisting of NIH-
funded HMP scientists, physicians, legal academics, government regulators, industry and 
consumer representatives, bioethicists, food and drug lawyers, and health policymakers 
who were assembled to address the adequacy of the current regulatory framework for 
probiotics under the HMP ELSI funded project.14 Specifically, after discussion of the 
features of probiotics that are relevant to their regulation and an overview of FDA’s 
current regulation of probiotics, the article addresses the following questions: 1) Do 
current regulations adequately address the safety of new probiotic products? 2) Should 
probiotic foods and dietary supplements be classified as drugs and required to go through 
the drug approval process? 3) What types of product characterization requirements are 
appropriate for probiotics? 4) Are current claim regulations appropriate for probiotics 
and, if not, how might they be improved?
11 The grant was awarded to researchers at the University of Maryland, Baltimore and was an 
interdisciplinary collaboration between faculty members from the University of Maryland Schools of Law, 
Pharmacy and Medicine. See Grant Number, supra note 1. 
12 See Jon A. Vanderhoof & Rosemary Young, Probiotics in the United States, 46 CliniCal infeCtious 
diseases S67, S67 (2008) (“Although the use and scientific understanding of probiotics are rapidly increasing, 
it is evident that there is a need to clarify the regulatory issues, which, at present, are unclear and subject to 
misinterpretation.”). See also Freddie Ann Hoffman et al., Executive Summary: Scientific and Regulatory 
Challenges of Development of Probiotics as Foods and Drugs, 46 CliniCal infeCtious diseases S53 (2008); 
Diane E. Hoffmann et al., Probiotics: Finding the Right Regulatory Balance, 342 sCienCe 314 (2013). 
13 See, e.g., Hoffmann et al., supra note 12.
14 See Grant Number, supra note 1. The NIH grant funded a number of meetings of the Working 
Group (WG). A list of WG members is available at http://www.law.umaryland.edu/programs/health/events/
probiotics/documents/Probiotic_Participant_list.pdf. While this article reflects the discussions of the WG, it 
is not a consensus document. It is written from the perspective of the authors, who considered the relevant 
literature as well as the opinions of the WG members in drafting this paper.
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ii. FeAtureS oF probioticS reLevAnt to reguLAtion 
A. Nature of Probiotics
A foundational question in determining the appropriate regulatory framework(s) 
for probiotics is whether probiotics have intrinsic and distinct characteristics that 
sufficiently distinguish them from other FDA regulated products. While probiotics 
share characteristics with other regulated products, as a group, probiotics have a clearly 
defined set of characteristics that should be taken into consideration in the regulatory 
process. By their very nature, probiotics are live organisms that are dynamic and thus 
unlike chemicals. Probiotics are also likely to lose viability and degrade under certain 
circumstances.15 As a result, probiotic research and manufacturing involve a greater 
number of variables than research with many other substances, such as the effect of 
the environment on the viability and effectiveness of the probiotic; the interaction 
between the human genome and the human microbiota; and triggers within the human 
body that may activate or deactivate the probiotic.16 Thus, without quality control, 
“specific probiotics may lose the properties that once formed their isolation and selection 
criteria.”17 Animal models may be of limited utility in probiotic research because of 
the complexity of the human microbiome and the major differences between human 
microbiomes and animal microbiomes.18 Given these differences, dosing of probiotics 
for therapeutic purposes is more problematic, as is manufacture, storage, and shelf 
life. Similar to botanicals, there are differences that appear from batch to batch when 
manufacturing probiotics. Finally, unlike other products, probiotics are often derived 
from microbes living in human bodies. While the import of these intrinsic characteristics 
may be difficult to translate into regulatory processes, they should be the foundation 
from which we contemplate how probiotics are regulated.
In addition to the intrinsic characteristics of probiotics as live microorganisms that 
differentiate them from most other health-related products, another unique feature of 
probiotics is that many are intended to promote human wellness and the balance of the 
microbiota in the gut, mouth, and other body sites where microbial communities exist. 
Although the HMP and related research are likely to lead to therapeutic (i.e., drug) uses 
for certain probiotics, many stakeholders in the world of probiotics understand that 
most probiotics play a role that is unlike that of drugs. As a result, the large majority 
of probiotics are now sold as foods and dietary supplements. The field of probiotics 
contemplates the role of foods in preventing or reducing disease and illness. Many 
of those conducting research on probiotics believe probiotics in food are useful for, 
15 See Hoffmann et al., supra note 12. See also Andi L. Shane et al., Guide to Designing, Conducting, 
Publishing and Communicating Results of Clinical Studies Involving Probiotic Applications in Human 
Participants, 1 gut MiCrobes 243, 246 (2010) (stating that a “unique aspect of probiotics is their viable 
nature”).
16 See Hoffmann et al., supra note 12. 
17 Id. at 314 (citing Grzekowiak et al., Manufacturing Process Influences Properties of Probiotic 
Bacteria, 105 brit. J. nutrition 887 (2011)).
18 See id. See also Shane et al., supra note 15, at 249 (“For most chemical substances, most of the 
burden of evaluating safety falls on tests performed on well-understood animal models. For the safety-related 
endpoints important in the assessment of probiotics, validated animal models do not exist and, as a result, 
the determination of safety rests primarily on human studies.”). See also James T. Heimbach, Health-Benefit 
Claims for Probiotic Products, 46 CliniCal infeCtious diseases S122, S124 (2008) (asserting that, although 
animal and in vitro studies may be helpful in establishing the biological mechanism of therapies, the use of 
an appropriate animal model with probiotics is challenging “because there has been little published research 
demonstrating that rats, mice, or other frequently used laboratory animals are valid models for the safety or 
efficacy of probiotic microorganisms in the human”).
2014 241Probiotics: Achieving A better regulAtory Fit
among other things, dietary management to reduce the risk of acute diseases (colds, 
flu, gastrointestinal infections); mitigation of symptoms in persons who are not fully 
healthy (irritable bowel syndrome); improvement of the therapeutic efficacy of a drug; 
and management of the side effects of a drug (such as the side effects of an antibiotic). 
B. Safety of Probiotics 
A recent article on the safety of probiotics begins with the statement that “[a]ny 
discussion of probiotic safety would be misleading were it not to acknowledge the 
remarkably low rate of adverse events recorded with probiotic consumption, either as 
specific products in the context of controlled trials or as constituents in fermented food 
products, over a long history of widespread use.”19 The article goes on to say, however, 
that “there are important caveats regarding probiotic safety that need emphasis.”20 
The available literature indicates that safety evaluations of probiotics should consider 
“pathogenicity, infectivity, virulence factors, toxicity, metabolic activity and intrinsic 
properties of the microbes.”21 Evidence exists that specific strains of probiotics are safe 
for human use, but for other strains there is limited data on safety. This underscores 
the point that probiotic bacteria are heterogeneous and should be evaluated for safety 
individually on a “strain-by-strain basis.”22
This point is exemplified by the issue of lateral gene transfer, which refers to the 
transfer of genetic material between organisms other than from vertical transmission, 
i.e., gene exchange from the parental generation to the offspring. Lateral gene transfer 
is a mechanism of gene exchange that happens independently of reproduction and is 
one of the mechanisms for the transfer of bacterial antibiotic resistance.23 Genes that 
are responsible for antibiotic resistance in one species of bacteria can be transferred to 
another species of bacteria through various mechanisms. There is no evidence of this 
having happened with probiotics to date, but it is important to the extent that probiotic 
therapy is often used or recommended in conjunction with antibiotics.24
In 2009, the Agency for Healthcare Research and Quality (AHRQ) commissioned the 
Southern California Evidence-based Practice Center, based at the RAND Institute, to 
carry out a systematic review of the safety of probiotics used in research to reduce the 
risk of, prevent, or treat disease.25 In April 2011, AHRQ published the most extensive 
report to date on the safety of probiotics based on this review. The report cataloged “what 
is known about the safety of interventions containing Lactobacillus, Bifidobacterium, 
Saccharomyces, Streptococcus, Enterococcus, and/or Bacillus strains used as probiotic 
agents in research to reduce the risk of, prevent, or treat disease.” 26 
19 Fergus Shanahan, A Commentary on the Safety of Probiotics, 41 gastroenterology CliniCs n. aM. 
869, 869 (2012).
20 Id.
21 Christophe Chassard et al., Probiotics and Health Claims: Challenges for Tailoring Their Efficacy, 
in probiotiCs & HealtH ClaiMs 51 (Wolfgang Kneifel & Seppo Salminen eds., 2011) (citing Norio Ishibashi 
& Shoji Yamazaki, Probiotics and Safety, 73 aM. J. CliniCal nutrition 465S (2001)).
22 See Shanahan, supra note 19, at 874. 
23 See oeCd, safety assessMent of transgeniC organisMs, voluMe 4: oeCd Consensus doCuMents 
171–74 (2010).
24 One response to this concern is to require testing to determine the antibiotic resistance patterns of 
probiotics at the strain level and to eliminate the possibility of the probiotic strain(s) carrying transmissible 
antibiotic resistance genes.
25 The evidence report was jointly sponsored by the NIH Office of Dietary Supplements, the NIH 
National Center for Complementary and Alternative Medicine (NCCAM), and the FDA’s Center for Food 
Safety and Applied Nutrition (CFSAN). 
26 agenCy for HealtHCare researCH & Quality, safety of probiotiCs to reduCe risk and prevent 
            Vol. 69242 Food and drug Law JournaL
The researchers identified 622 intervention studies on probiotics that reported 
the presence or absence of adverse health outcomes in human participants, without 
restriction by study design, participant type, or clinical field. The investigators were 
unable to make broad conclusions about the safety of probiotics because “[t]here is a 
lack of assessment and systematic reporting of adverse events in probiotic intervention 
studies, and interventions are poorly documented.”27 In 235 studies, only nonspecific 
safety statements were made (e.g., the product is “well tolerated”); the remaining 387 
studies reported the presence or absence of specific adverse events. The conclusion of 
the AHRQ report was hindered by the lack of well-documented studies and the authors 
could only conclude that “[t]he available evidence in RCTs [randomized controlled trials] 
does not indicate an increased risk; however, rare adverse events are difficult to assess, 
and despite the substantial number of publications, the current literature is not well 
equipped to answer questions on the safety of probiotic interventions with confidence.”28 
More specifically, the authors noted that, based on reported adverse events, RCTs 
showed no statistically significant increased risk of adverse events, including serious 
adverse events, associated with short-term probiotic use compared to control group 
participants. Long-term effects are largely unknown. Existing studies primarily examined 
Lactobacillus alone or in combination with other genera, often Bifidobacterium. Few 
studies directly compared safety-related outcomes among different interventions or 
participant subgroups. Indirect comparisons indicated that effects of delivery vehicles 
(e.g., yogurt, other dairy products) should be investigated further. Case studies suggested 
that participants with compromised health are most likely to experience adverse events 
associated with probiotics. However, RCTs in medium-risk and critically ill participants 
did not report a statistically significant increased risk of adverse events compared to 
control group participants.
C. Environmental Risk
Another unique feature of probiotics is their potential effect on the environment. The 
effects of probiotics released into the environment, their ability to multiply, and the 
possibility that they may have adverse environmental effects, has not been studied. The 
need for such research is particularly important in the case of genetically engineered 
probiotics. Issues of environmental regulation, however, are beyond the scope of this 
article.
iii. current reguLAtion oF probioticS by the FdA
The primary agency with regulatory authority over probiotics is the FDA, although 
the Federal Trade Commission (FTC), through its authority to regulate certain aspects 
of product advertising and marketing, also regulates probiotics. The FDA, unlike the 
or treat disease, at vi (2011), available at http://www.ahrq.gov/research/findings/evidence-based-reports/
probiotic-evidence-report.pdf.
27 Id. 
28 Id. Critics have asserted that the report provided “little guidance to the healthcare and nutrition 
communities” because it relied primarily on a drug-oriented, evidence-based medicine paradigm instead of 
an evidence-based evaluation of other forms of data and practical information. Taylor C. Wallace & Douglas 
MacKay, The Safety of Probiotics: Considerations Following the 2011 U.S. Agency for Health Research and 
Quality Report, 141 J. nutrition 1923, 1924 (2011). The authors argued that “in the absence of drug-like 
safety data, the safety of traditional foods should be based on the totality of evidence in healthy populations.” 
Id. at 1923 (emphasis added). They define totality of evidence as including “history of safe use as well as 
RCT, epidemiological data, animal studies, and in vitro cell work . . . .” Id.
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FTC, regulates products by category, e.g., foods, drugs (including biologics), dietary 
supplements, medical devices, and cosmetics.
The FDA places products in categories by their intended use. Intended use is typically 
determined by claims which the manufacturer wants to make about the product rather 
than its ingredients or other characteristics. Particularly relevant to the regulation of 
probiotics are the following product categories: foods;29 substances within the food 
class, i.e., food additives,30 substances generally regarded as safe (GRAS),31 medical 
foods,32 and foods for special dietary use;33 dietary supplements;34 cosmetics;35 medical 
devices;36 and drugs.37 
Each product category is regulated by a center at the FDA that evaluates and monitors 
many aspects of the life cycle of a product. Of most relevance to the regulation of 
probiotics for human use are the Center for Food Safety and Applied Nutrition (CFSAN), 
the Center for Drug Evaluation and Research (CDER), and the Center for Biologics 
Evaluation and Research (CBER).
In addition to the centers devoted to a specific product class, the FDA’s Office of 
Combination Products (“OCP”) responds both formally and informally to industry 
inquiries about which FDA center should regulate a particular product. Where a product 
contains, for example, a drug and a biologic or a drug and a medical device, it is termed 
a “combination product”38 and regulated according to its primary mode of action.39 
Industry or FDA centers can seek the guidance of the OCP to determine (1) which center 
should regulate a non-combination product when jurisdiction is unclear; and (2) which 
center should have primary jurisdiction in the case of a proposed combination product.40 
Probiotics have traditionally appeared in foods, which, along with cosmetics, are 
among the least regulated products consumers use in or on their bodies. To this day, 
the most well-known probiotic products are yogurts. However, in the last decade, 
probiotics have appeared in an increasing number of non-food products such as dietary 
29 FDCA Sec. 201(f) (codified at 21 U.S.C. § 321(f)).
30 FDCA, Secs. 201(s), 409 (codified at 21 U.S.C. §§ 321(s), 348); 21 C.F.R. § 170.30 (2013).
31 FDCA, Secs. 201(s), 409; 21 C.F.R. § 170.30 (2013).
32 Section 5(b) of the Orphan Drug Act, 21 U.S.C. § 360ee(b)(3) (2012).
33 Foods for special dietary use are a narrow category of foods that FDA defines as “foods that are 
specially formulated to meet a special dietary need, such as a food allergy or difficulty in swallowing, but 
that provide nutrients intended to meet ordinary nutritional requirements.” By regulation, FDA has approved 
label statements for three categories of foods for special dietary use—hypoallergenic foods, infant foods 
and food “that purports to be or is represented for special dietary use because of usefulness in reducing or 
maintaining body weight.” 21 C.F.R. §§ 105.66, 105.62, 105.65 (2013). 
34 Dietary Supplement Health & Education Act (DSHEA) of 1994, FDCA Sec. 413(c) (codified at 21 
U.S.C. § 350(b)).
35 FDCA, Sec. 201(i) (codified at 21 U.S.C. § 321(i)).
36 21 U.S.C. § 321(h) (2012).
37 21 U.S.C. § 321(g)(1) (2012).
38 The OCP was established in 2002 and determines regulatory responsibilities for products combining 
elements of drugs, devices, and biologics among the relevant centers—CDER, CBER, and the Center for 
Devices and Radiological Health. See Combination Products, food & drug adMin., http://www.fda.gov/
CombinationProducts/ (last visited Jan. 31, 2014). 
39 See Jordan Paradise, Reassessing Safety for Nanotechnology Combination Products: What Do 
Biosimilars Add to Regulatory Challenges for the FDA?, 56 st. louis u. l.J. 465 (2012). 
40 See Frequently Asked Questions About Combination Products, food & drug adMin, http://www.
fda.gov/CombinationProducts/AboutCombinationProducts/ucm101496.htm (last visited Jan. 31, 2014).
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supplements and cosmetics.41 There are also probiotic products that could fall into the 
medical device category, such as probiotic tampons.42 
While probiotics fall (or will fall) into virtually every product category regulated 
by the FDA, to date, the FDA does not have a central office or pathway that deals 
specifically with probiotics. Nor does the agency have a regulatory definition of 
probiotics. When questions arise regarding into which category a probiotic belongs, 
the answer is determined on a case-by-case basis. The issue of category assignment 
is of significant import for probiotic manufacturers and researchers. Classification as 
a drug triggers the extensive and costly Investigational New Drug application (IND) 
process, which typically includes Phase I, II, and III clinical trials. All drugs must be 
approved prior to marketing by the FDA. Foods and dietary supplements, however, do 
not require agency premarket approval. 
The current regulatory framework does not address the role of foods in treating, 
mitigating, or curing disease. Probiotic foods and dietary supplements that attempt to 
take on such a role are automatically placed in the drug category. According to some, 
the “regulatory box paradigm” adopted by the U.S. and many other countries “imposes 
substantial hurdles for research, consumer understanding and marketing of functional 
foods,” i.e. foods that may play a role in improving health and treating disease.43 
Because probiotics fall into multiple product categories, some experts in the field argue 
that expertise about probiotics is spread unevenly across multiple centers at the FDA 
without a single authoritative agency voice on the issue. This may lead to inter-center 
inconsistencies in interpretation and application of regulations, data requirements, and 
the content of potentially relevant guidance documents about probiotics. Furthermore, 
some believe, in the absence of a clear FDA position on regulation of probiotics, CBER 
may be the default center to review any probiotic given that recent CBER guidance 
implies that probiotics are live biotherapeutics44—a category of products considered 
drugs. CBER, however, may not always be the most appropriate center to regulate 
probiotics traditionally found in foods or sold as dietary supplements with added 
microorganisms. 
iv. do current reguLAtionS AdequAteLy AddreSS  
the SAFety oF new probiotic productS?
Safety is an overarching concern among all probiotic stakeholders, from government 
regulatory agencies, to consumer advocacy organizations, to manufacturers. In order for 
the potential of probiotics to be realized, probiotic products must be safe in both practice 
and perception. Although current FDA safety standards for foods, food additives, and 
41 For example, Align, a daily probiotic supplement containing Bifidobacterium infantis (BifantisTM) 
bacteria, made by Procter and Gamble, and Redness Solutions Makeup SPF 15 with Probiotic Technology, 
made by Clinique are both probiotic cosmetics. Although probiotics can be cosmetics, the WG did not focus 
on probiotics that fall into the cosmetic product category. 
42 An example is the Saforelle Florgynal Probiotic Tampon. Tampons have traditionally been regulated 
as medical devices. See, e.g., 21 C.F.R. § 884.5470 (2013).
43 Mary Ellen Sanders et al., Health Claims Substantiation for Probiotic and Prebiotic Products, 2 
gut MiCrobes 127 (2011). Others argue that FDA’s regulatory scheme assumes a more distinct and rigid 
line between categories and the role of products in each category than is reflected by the complex and fluid 
biology underlying concepts such as “health” and “disease.” See, e.g., Jeffrey Blumberg et al., Evidence-based 
Criteria in the Nutritional Context, 68 nutrition rev. 478, 480 (2010). 
44 See food & drug adMin., guidanCe for industry: early CliniCal trials WitH live biotHerapeutiC 
produCts: CHeMistry, ManufaCturing, and Control inforMation (Feb. 2012), available at http://www.
fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/general/
ucm292704.pdf ; see also infra note 80 and accompanying text.
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drugs appear largely adequate for probiotics, some aspects of probiotic safety regulation 
could be improved.
A. Safety of Probiotic Foods
The safety of foods and food components are generally not studied via RCTs,45 and 
few foods have in fact been subject to toxicological studies.46 Many of the studies on 
safety in probiotic foods have been non-controlled randomized studies; non-randomized 
controlled studies; or observational studies including cohort studies, case-control 
studies, cross-sectional studies, and case reports.47 Challenges to RCTs in foods include 
difficulties in preparing an appropriate placebo and accounting for simultaneous changes 
in an individual’s diet when a new food is introduced.48 Because of these challenges, food 
safety has often been determined by history of safe use where a food has been consumed 
for decades without significant adverse events.49 An internationally accepted criterion 
for a safe food is a reasonable certainty of no harm resulting from consumption.50
Despite the long history of apparently safe use of some probiotic foods, notably 
yogurt, one issue related to food safety that merits attention is the process by which 
a substance used in food is determined to be “generally recognized as safe” (GRAS). 
A substance may be established as GRAS either through scientific procedures or, for 
a substance used in food before 1958, through experience based on common use in 
food.51 The FDCA provides a mechanism for manufacturer self-determination of GRAS 
status and notification to the FDA prior to marketing of GRAS substances but does 
not require such notification. Prior to 1997, a manufacturer could submit a petition to 
FDA requesting GRAS affirmation. Since 1997, manufacturers have been allowed to 
(but need not) notify the FDA of their GRAS self-determination and provide evidence 
supporting their decision. After evaluating the notification, the FDA is to respond to 
the manufacturer, conveying the agency’s disposition within 90 days. The FDA may 
either “have no questions at this time” regarding the notice or indicate that the notice 
does not provide adequate basis for GRAS status. Critics have challenged various 
aspects of the GRAS process, including the wisdom of allowing food manufacturers to 
make their own GRAS determinations.52 To the extent that GRAS self-determination 
45 See Arthur C. Ouwehand et al., Probiotics: from Strain to Product, in probiotiCs & HealtH ClaiMs, 
supra note 21, at 46.
46 See A. Constable et al., History of Safe Use as Applied to the Safety Assessment of Novel Foods and 
Foods Derived from Genetically Modified Organisms, 45 food & CHeMiCal toxiCology 2513, 2513 (2007).
47 See Wallace & MacKay, supra note 28.
48 Ouwehand et al., supra note 45, at 46 (stating that “[i]f energy intake is to remain the same, something 
else will have to be excluded from the diet, with unknown consequences, something already noticed in the 
early days of cholesterol-lowering diets.” (citing George V. Mann & Anne Spoerry, Studies of a Surfactant 
and Cholestemia in the Maasai, 27 aM J. CliniCal nutrition 464 (1974))).
49 See Constable et al., supra note 46, at 2513.
50 Id.
51 FDCA, Secs. 201(s), 409 (codified at 21 U.S.C. §§ 321(s), 348); 21 C.F.R. § 170.30 (2013). Under 
21 C.F.R. § 170.30(c) and § 170.3(f), general recognition of safety through experience based on common 
use in foods requires, among other things, a substantial history of consumption of a substance for food use 
by a significant number of consumers.
52 See Letter from Gordon F. Tomaselli, Pres. of the American Heart Association, to the FDA and the 
USDA (Jan. 26, 2012), available at http://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/
downloadable/ucm_437039.pdf (regarding approaches to reducing sodium consumption.) See also u.s. 
gov’t aCCountability offiCe, gao-10-246, food safety: fda sHould strengtHen its oversigHt of food 
ingredients deterMined to be generally reCognized as safe (gras) (2010), available at http://www.gao.
gov/products/GAO-10-246. But, not all stakeholders agree with this assessment. See, e.g., Ray A. Matulka, 
The GRAS Process: Does It Need an Overhaul?, food & drug pol’y f., June 13, 2012, http://www.fdli.org/
            Vol. 69246 Food and drug Law JournaL
reflects limited regulatory oversight, the problem extends to probiotics. Despite this 
regulatory gap, FDA has approved a number of microorganisms and microbial-derived 
ingredients that are used in foods as GRAS.53 In addition, some probiotic manufacturers 
have submitted GRAS notifications to the agency, including at least four probiotics for 
use in infant formula. 54
B. Safety of Probiotic Dietary Supplements  
and Dietary Ingredients
A primary concern regarding the safety of probiotic dietary supplements is that the 
Dietary Supplement Health and Education Act (DSHEA) of 1994 “does not require 
manufacturers to submit dietary supplements to the FDA for safety testing or approval 
prior to sale.”55 While dietary supplement manufacturers, by law, must ensure that 
their products are safe, they need not submit data to the FDA substantiating how 
they established safety. However, the Dietary Supplement and Nonprescription Drug 
Consumer Protection Act of 2006 does require that the manufacturer of a dietary 
supplement marketed in the US “submit to FDA all serious adverse event reports 
associated with use of the dietary supplement in the United States.”56 Given that 
manufacturers do not need to register their products with FDA or obtain FDA approval 
before producing or selling dietary supplements, the FDA generally only takes action 
against the manufacturer after the product has been on the market and been shown to 
be unsafe.57 Moreover, the burden of proof to show that a dietary supplement is unsafe 
is on the FDA.58
resources/resources-order-box-detail-view/the-gras-process-does-it-need-an-overhaul- (subscription required) 
(asserting that the current GRAS process is adequate).
53 See Microorganisms and Microbial-Derived Ingredients Used in Food (Partial List), u.s. 
food & drug adMin. (July 2001), http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/
MicroorganismsMicrobialDerivedIngredients/default.htm.
54 These manufacturers include Ganeden Biotech, Yakult and several infant formula manufacturers. 
Ganaden Biotech received notice from the FDA in August 2012 that the agency had no questions or objections 
to the GRAS notification of GanedenBC30 (Bacillus coagulans GBI-30, 6086) for use as an ingredient in a 
range of foods and beverages. See Letter from Dennis M. Keefe, Dir., Office of Food Additive Safety, to John 
R. Endres, Chief Scientific Officer, AIBMR Life Sciences, Inc., Agency Response Letter to GRAS Notice No. 
GRN 000399 (July 31, 2012), available at http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/
NoticeInventory/ucm314145.htm. In April 2012, the Japanese company Yakult announced that an independent 
panel of scientists had evaluated Lactobacillus casei strain Shirota and determined that the strain is safe for 
use as a food ingredient. Yakult notified FDA of this GRAS self-determination in March 2012. See Letter 
from James T. Heimbach (for Yakult) to Paulette Gaynor, Supervisory Consumer Safety Advisor, FDA (Mar. 
20, 2012), available at http://www.accessdata.fda.gov/scripts/fcn/gras_notices/GRN000429.pdf. The FDA 
responded in December 2012 stating that it had no questions regarding Yakult’s self-determination of GRAS 
status. See Letter from Dennis M. Keefe, Dir., Office of Food Additive Safety to James T. Heimbach (Dec. 
10, 2012), available at http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/
ucm335746.htm. Infant formula manufacturers submitting GRAS Notifications to the FDA include Mead 
Johnson for Lactobacillus casei subsp. rhamnosus strain GG (GRAS Notification 231); Nestle Nutrition, US 
for Lactobacillus reuteri strain DSM 17938 (GRAS Notification 410); Fonterra Co-operative Group, New 
Zealand for Lactobacillus rhamnosus strain HN001 produced in milk-based medium, and Nestle USA for 
Bifidobacterium lactis strain Bb12 and Streptococcus thermophiles (GRAS Notification 49).
55 offiCe of inspeCtor general, u.s. dep’t of HealtH & HuM. servs., no. oei-01-11-00210, dietary 
suppleMents: struCture/funCtion ClaiMs fail to Meet federal reQuireMents (2012), available at https://
oig.hhs.gov/oei/reports/oei-01-11-00210.pdf. 
56 Dietary Supplements, u.s. food & drug adMin., www.fda.gov/Food/DietarySupplements/ (last 
visited Feb. 10, 2014).
57 Id.
58 See 21 U.S.C. § 342(f)(1) (2012).
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Inadequacies in the regulation of dietary supplements generally will have an impact 
on probiotic products but certain probiotics will be subject to enhanced regulation if 
the probiotic is considered a “new dietary ingredient” (NDI). If a probiotic is added to a 
dietary supplement, it is likely to be considered a “dietary ingredient” or NDI. If the latter, 
it will be subject to more extensive regulation than dietary supplements without NDIs. 
The law considers a dietary supplement that contains a “new dietary ingredient” (i.e., 
a dietary ingredient that was not marketed in the United States in a dietary supplement 
before Congress passed DSHEA on October 15, 1994) to be “adulterated unless it meets 
one of two statutory requirements: the supplement must contain only dietary ingredients 
that have been present in the food supply, or there must be a history of use or other 
evidence of safety establishing that the dietary ingredient will reasonably be expected 
to be safe.”59 The manufacturer must determine if the substance is an NDI and notify 
the FDA of its plan to market the NDI or to market the NDI in a dietary supplement 
75 days prior to marketing the product. The NDI notification must include supporting 
data that the dietary supplement containing the NDI will reasonably be expected to be 
safe under the supplement’s labeled conditions of use.60 The manufacturer must include 
evidence of a history of safe use, safety studies, or both.61 As of May 8, 2014 the FDA 
had not published guidance defining the specific information that the submission must 
contain.62 Rather, the agency has stated that the manufacturer or distributer is responsible 
for determining what information provides the basis for its conclusion but suggests that 
the submission include “evidence of safety found in the scientific literature, including 
an examination of adverse effects associated with the use of the substance.”63 
There is no authoritative, FDA-approved list of dietary ingredients that were marketed 
in dietary supplements before October, 1994. Although trade associations have created 
59 offiCe of tHe inspeCtor general, supra note 55, at 2 n.16 (citing 21 U.S.C. § 350b). In the 2011 FDA 
guidance relating to NDIs, the safety of an NDI can be established based on history of safe use. According 
to the guidance, 
An important component of reliability [of data relating to safe use] is the length of an 
ingredient’s history of use. A description of the population and the ways in which they use 
the food is also important. The frequency of food consumption and the number of consumers 
who used the food are at least as important as the number of years over which the product 
was available. Because there is little scientific literature addressing this topic, FDA cannot 
make specific recommendations at this time, although the agency considers 25 years of 
widespread use to be the minimum to establish a history of safe use. 
See Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and 
Related Issues, u.s. food & drug adMin. (July 2011), http://www.fda.gov/Food/GuidanceRegulation/
GuidanceDocumentsRegulatoryInformation/DietarySupplements/ucm257563.htm [hereinafter Draft 
Guidance for Industry: New Dietary Ingredient Notifications].
60 See 21 U.S.C. § 350b(a)(2) (2012).
61 See Draft Guidance for Industry, New Dietary Ingredient Notifications, supra note 59. 
62 New Dietary Ingredients in Dietary Supplements – Background for Industry, u.s. food & drug 
adMin., www.fda.gov/Food/DietarySupplements/ucm109764.htm (last visited May 8, 2014). 
63 Id. Experts in the field have recommended that 
the submission identify any pathogens phylogenetically related at the species and genus 
level; identify toxins or other dangerous substances known to be present in the same species; 
document and detail any known antibiotic resistance (assess the ability of resistant genes 
to mobilize and transfer pathogens); assess, for historical use data, the level of historical 
exposure including how any excipients used in it affect delivery of the NDI tract; and include, 
if historical use is inadequate, safety studies in humans or appropriate animal models. Human 
safety studies should include measurements of the persistence of the organisms in the body 
after administration, the ability of the organism to translocate outside of the gastrointestinal 
tract, and tolerance of the ingredient using the proposed serving form. 
See Steve Myers, Probiotics, NDIs and Species Identification, supplyside MarketplaCe 3 (June 2012), 
available at http://www.accugenix.com/media/asset-probiotics-ndis-and-species-identification.pdf.
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a number of such lists, including the probiotics listed below,64 there remains some 
uncertainty as to whether the FDA considers them grandfathered.65 The burden of proof 
is on the FDA to show that these substances were not marketed before 1994.66 Probiotics 
marketed before 1994 include:67
•	 Bifidobacterium bifidum
•	 Bifidobacterium infantis
•	 Bifidobacterium longum
•	 Bifidus adolescentis
•	 Lactobacillus acidophilus
•	 Lactobacillus casei
•	 Lactobacillus jugartldelbrueckii (bulgaricus)
•	 Lactobacillus plantarum
•	 Lactobacillus rhamnosus
•	 Saccharamyces boulardii
•	 Streptococcus faecium (Enierococcus faecium)
•	 Streptococcus salivarius
•	 Streptococcus thermophilus
C. History of Safe Use
The FDA uses history of safe use to establish the safety of substances in several 
categories of regulated products, including GRAS substances and NDIs. While we 
agree that historical use should be used to establish safety in probiotics, there are several 
caveats to this recommendation. History of safe use should be considered only if the 
same target population and essentially the same dose and delivery system are to be used 
in the proposed use. The more the proposed use of the probiotic departs from historical 
usage in terms of the target population, dose, or delivery system, the more persuasive 
the argument that additional safety analysis should be required. While many probiotics 
do have a long history of safe use, new probiotics that have not been on the market or 
those belonging to a species for which safety cannot be presumed should be required to 
go through more rigorous safety assessment, with appropriately designed study methods.
v. ShouLd probiotic FoodS or dietAry SuppLementS be 
cLASSiFied AS drugS And required to go through the 
drug ApprovAL proceSS?
A major concern relating to probiotic regulation is when and whether a researcher or 
manufacturer conducting research on the benefits of a probiotic product must conform to 
the rigorous and costly IND process. This is a question that is increasingly being asked 
by institutional review boards (IRBs) that are receiving applications “that propose the use 
of dietary supplements, foods, food-derived products regulated as dietary ingredients”68 
64 See Myers, supra note 63.
65 Because probiotics can be characterized at different levels (i.e., strain, species, etc.), some in the 
probiotics industry have argued that use of a new strain within a microbial species that was present in the 
food supply before 1994 should not constitute a new dietary ingredient. int’l probiotiCs ass’n, european 
food & feed Cultures ass’n & int’l food additives CounCil, position paper (May 2011), available at 
http://www.internationalprobiotics.org/files/news/7/11.pdf. 
66 See Myers, supra note 63. 
67 Id.
68 See Research Involving Food or Food-Derived Products, Spices/Herbs, or Dietary Supplements, 
JoHns Hopkins MediCine (Apr. 2012), http://www.hopkinsmedicine.org/institutional_review_board/guidelines_
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as part of a clinical trial.69 NIH and the FDA may require an IND for studies relating 
to probiotics even in cases where an IND may not be required or appropriate, such 
as studies with probiotics that have a history of safe use in the target population. The 
fact that the proposed research use would not increase risk to subjects in comparison 
to risks to consumers of products that are already legally marketed as a food may not 
be determinative of whether an IND is required.70 Moreover, “there are no categorical 
determinations in this regard; for the same product, INDs may be required for some 
studies and not for others.”71 
The IND requirement has been a significant problem for some investigator-initiated 
researchers. Under the investigator-initiated IND process, academic or independent 
researchers must depend on the cooperation of the product manufacturer to obtain 
necessary information. If the company does not want the study conducted, it can 
essentially block it by refusing to provide the necessary background data required for 
an IND.
A. Probiotics and Research Endpoints
Whether or not the proposed research is subject to an IND often depends on the 
studied indication. If a clinical research trial measures an outcome that relates to a 
substance’s ability to diagnose, cure, mitigate, treat, or prevent disease, and the study will 
be used to make claims about the substance (e.g., substance X lowers blood pressure), 
the FDA will consider the substance a drug. The measured outcomes are considered 
“disease endpoints”. Use of a disease endpoint has two important consequences: first, 
the research becomes drug research72 and is therefore subject to higher levels of scrutiny 
and human subject protection than research on non-drug substances. Second, the research 
cannot be used to support product claims for foods and dietary supplements, which 
are not permitted to make drug claims.73 Because probiotics generally promote health 
and wellness, many of the studies that have been undertaken on probiotics have been 
conducted using endpoints that FDA considers disease endpoints, thereby rendering them 
drugs. This is the case even if the product has been marketed as a food. The traditional 
definition of “drug” does not consider the use of food products to promote a healthy 
balance of the microbiota, the role of such products in generally healthy individuals, 
or the role of food in promoting health. 
The implications of this are illustrated by a 2010 study which tested a fermented 
milk’s ability to reduce the incidence of common infectious diseases (CIDs) in healthy 
children in day care centers.74 Even though the study documented a decreased incidence 
rate for CIDs in the active group by 19 percent compared to a control group, use of the 
policies/guidelines/ind_not_drugs.html.
69 An IND is required for a clinical study if it is intended to support a new indication for a drug, a 
change in the approved route of administration or dosage level, a change in the approved patient population 
or a population at increased risk of harms associated with the drug, or a significant change in the promotion 
of an approved drug. See 21 C.F.R. § 312.2 (2013).
70 See JoHns Hopkins MediCine, supra note 68.
71 Id.
72 See Fred Degnan, Clinical Studies Involving Probiotics: When FDA’s Investigational New Drug 
Rubric Applies and When it May Not, 3 gut MiCrobes 1 (2012). See also JoHns Hopkins MediCine, supra 
note 68. 
73 Id. As discussed infra, notes 114-125 and accompanying text, there are narrow exceptions to this 
prohibition.
74 D. Merenstein et al., Use of a Fermented Dairy Probiotic Drink Containing Lactobacillus casei 
(DN-114 001) to Decrease the Rate of Illness in Kids: the DRINK Study, a Patient-Oriented, Double-Blind, 
Cluster-Randomized, Placebo-Controlled, Clinical Trial, 64 eur. J. CliniCal nutrition 669 (2010). 
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product in this study to prevent CIDs in day care children would be considered a drug 
use. Under the current FDA framework for claims, this study could only be used to 
substantiate a drug claim. If the manufacturer of the fermented milk made a claim that 
referred to this study, the milk would be considered a drug. 
Some believe this result to be over-regulation and assert that it will have a chilling 
effect on research designed to test the therapeutic properties of probiotic foods and 
dietary substances. The lack of such research may deprive patients and consumers of 
beneficial information. The ability to conduct research with disease endpoints would 
provide greater opportunities to conduct basic research on probiotic foods and dietary 
supplements. However, researchers and manufacturers are concerned that, under the 
current regulatory framework, studies with disease endpoints will take their products 
into the drug category and out of the food and dietary supplement market where they 
believe most of these products belong.
Compounding this problem is the paucity of non-disease endpoints. It is challenging to 
measure health maintenance, healthy balance of microbiota, or improvement in wellness 
of a healthy person. Some researchers have suggested that the focus of probiotic studies 
could be in measurement of homeostasis, a term referring to stability in physiological 
parameters.75 From a statistical point of view, if a study were able to minimize the 
variation around the mean for a specific measure (even in the absence of changing the 
mean), it could be a reflection of improved health. This notion, proposed by Dr. Daniel 
Tancredi, emphasizes the importance of homeostasis as a focus of studies on health 
(as opposed to disease), and provides a rationale based in solid statistical theory as a 
way to measure wellness or health maintenance. According to an article co-authored 
by Tancredi, 76 one challenge to demonstrating the value of this approach is to identify 
appropriate biomarkers that can be studied. The article notes that the following properties 
would be important in a biomarker:
•	 maintaining moderate levels of the biomarker would be associated with good 
health;
•	 high or low values would be associated with ill health;
•	 biomarker levels in the same person would fluctuate over time; and
•	 reducing the magnitude or duration of such fluctuations in healthy people would 
be considered desirable.77
Such a biomarker could be an individual endpoint or be formed as a ratio of two 
other biomarkers when maintaining the same relative amounts of the two component 
biomarkers would be desirable.78 Assuming a biomarker with the above properties is 
available, it could be used as the outcome measure in a randomized controlled trial 
to provide evidence that the experimental food is able to improve the maintenance of 
health in humans. As an example, in pediatric nutrition, the measurement of metabolic 
homeostasis is the standard approach when developing infant formulas.79
75 L. Michael Romero et al., The Reactive Scope Model – A New Model Integrating Homeostasis, 
Allostasis, and Stress, 55 HorMones & beHav. 375, 376 (2009).
76 Mary Ellen Sanders et al., Health Claims Substantiation for Probiotic and Prebiotic Products, 2 
gut MiCrobes 127 (2011).
77 Id.
78 Id.
79 Id.
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B. Probiotics as Live Biotherapeutic Products Subject  
to IND Requirements 
In addition to requiring INDs for research with disease endpoints, FDA considers 
probiotics to be live biotherapeutic products (LBPs) subject to IND requirements. In 
2010, the FDA published draft FDA guidance80 that appeared to define all probiotics 
as live biotherapeutic products (which are drugs) and therefore would require all 
probiotics—including ones being marketed as foods or dietary supplements—to go 
through the IND process. This appeared to be the case even if the product manufacturer 
intended the research to test claims that are legal for foods (i.e., structure/function 
(S/F), risk reduction, or medical food claims). This articulation of the law is troubling 
to many stakeholders and may be inappropriate and inaccurate under current law given 
that, historically, assignment of a particular use of a substance or microorganism was 
properly based on the claims made, rather than on the nature of the research supporting 
those claims. 
In February 2012, this concern was addressed to a certain degree by the FDA. In 
final guidance relating to clinical trials with LBPs, the FDA stated that “[t]his guidance 
. . . does not apply to products lawfully marketed as conventional foods or dietary 
supplements that are proposed for investigation solely to evaluate an LBP’s use in 
affecting the structure or any function of the body.”81 As such, it appeared that an IND 
would not be required for studies of foods and dietary supplements that are conducted to 
make S/F claims. However, this impression was dispelled in September 2013 when the 
FDA published guidance relating to INDs and human research studies.82 In this guidance, 
the FDA clearly indicated that an IND would be required for clinical investigations to 
substantiate both drug and S/F claims. Under the new guidance, it seems that the only 
food studies that will be allowed by the FDA to substantiate an S/F claim are those that 
relate to the food’s taste, aroma, and nutritive value.83 The guidance notes
[i]f an edible product that might otherwise be a conventional food is 
intended for a use other than providing taste, aroma, or nutritive value, such 
as blocking the absorption of carbohydrates in the gut, that product becomes 
a drug because the primary purpose of consuming it has changed. In other 
words, the product is no longer being consumed as a food—primarily 
for taste, aroma, or nutritive value—but used as a drug for some other 
physiological effect.84 
 This new guidance raises multiple concerns. The first is that it appears to support a 
broader interpretation of the definition of drug than has been used in the past. As noted 
earlier, the definition of drug is any article “(other than food) intended to affect the 
structure or any function of the body of man or other animals.”85 The “other than food” 
80 See Draft Guidance for Industry: Early Clinical Trials with Live Biotherapeutic Products: Chemistry, 
Manufacturing, and Control Information, 75 Fed. Reg. 63,188 (Oct. 14, 2010). 
81 See fda, guidanCe for industry, supra note 44. 
82 food & drug adMin., guidanCe for industry investigational neW drug appliCations (inds)—
deterMining WHetHer HuMan researCH studies Can be ConduCted WitHout an ind (Sept. 2013), available 
at http://www.fda.gov/downloads/Drugs/.../Guidances/UCM229175.pdf [hereinafter ind guidanCe for 
industry]. 
83 Id. 
84 Id.
85 Food, Drug & Cosmetic Act of 1938 (FDCA), Pub. L. No. 75-717, Sec. 201(g), 52 Stat. 1040, 1041 
(codified at 21 U.S.C. § 321(g)).
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construction has typically been interpreted to mean that S/F claims are acceptable for 
foods and, in fact, most probiotic products now on the US market make S/F claims.86 
Although the guidance relates to human research and does not by its terms affect product 
claims, one expert noted that “if you can’t do the research to support a product claim, 
you’ll never be able to make a product claim.”87 Based on FDA’s most recent guidance, 
it appears that the only avenue to study the effect of food on the structure and/or function 
of the human body is through its taste, aroma or nutritive value. So, for example, under 
this guidance, a study could not be used to show increased balance of gut microflora 
(a typical S/F claim used currently) because such a study does not relate to the taste, 
aroma, or nutritive value of the food. Further, critics have noted that the guidance will 
make it difficult to conduct studies of novel medical foods by requiring that research 
on medical food be conducted under an IND.88
C. The “Lock-In” Problem
A further concern raised by the 2013 guidance relates to the statutory “lock in” 
provision created by section 912 of the FDA Amendments Act of 2007, which added 
subsection 301(ll) to the FDCA, prohibiting the sale of food to which any of the following 
have been added: a drug, licensed biological product, or biological product for which 
“substantial clinical investigations” have been instituted. From a historical perspective, 
this marks a significant change in the regulation of food and drugs. Prior to the advent 
of subsection 301(ll), there was considerable flexibility in the regulatory categorization 
of a substance as a food, a drug, or both. This “lock in” provision potentially prohibits 
the marketing of a food where the food is first studied under an IND, even if the study 
is ultimately intended to support food, rather than drug, use of the product.89 
The 2013 guidance makes specific reference to subsection 301(ll) and warns that those 
who conduct or sponsor research intended to support labeling claims for conventional 
foods or dietary supplements should be aware that subsection 301(ll) may “restrict the 
marketing of products containing substances that have been the subject of ‘substantial 
clinical investigations’ whose existence has been made public.”90 The guidance offers the 
suggestion that “[m]arketing the substance of interest [as a dietary supplement or food] 
before seeking an IND or beginning any clinical investigations preserves the option to 
continue to market the substance in those forms after substantial clinical investigations 
86 Although the 2013 guidance references Nutrilab v. Schweiker, 713 F.2d 335 (7th Cir. 1983), as 
support for its narrow interpretation of the “other than food” exception, at least one commentator has noted 
that FDA’s interpretation “is in direct conflict with the opinion of the Seventh Circuit as well as subsequent 
case law that relied on Nutrilab.” Wes Siegner & Paul M. Hyman, Medical Food Mumbo Jumbo: Confusing 
FDA Guidance Documents Will Discourage Medical Food Development, fda laW blog (Sept. 18, 2013), 
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2013/09/medical-food-mumbo-jumbo-confusing-
fda-guidance-documents-will-discourage-medical-food-development.html. Siegner and Hyman also note in 
their blog that one court specifically used the Nutrilab case to support the proposition that the “other than 
food” exception “suggests that Congress did not want to inhibit the dissemination of useful information 
concerning a food’s physiological properties by subjecting foods to drug regulation . . . .” Id. (quoting Am. 
Health Prods. Co., Inc. v. Hayes, 574 F. Supp. 1498, 1507 (S.D.N.Y. 1983).
87 Mary Ellen Sanders, Human Research, Functional Foods and the FDA, Cal. dairy res. found. 
blog (Oct. 20, 2013), http://cdrf.org/2013/10/20/human-research-functional-foods-and-the-fda/. 
88 Siegner & Hyman, supra note 86. See also Letter to FDA signed by 62 food science and nutrition 
academics who wrote that the guidance would “have a paralyzing effect on clinical research in the U.S. and 
stifle innovation and product development” in food research. Letter from Prof. Connie Weaver, Purdue Univ., 
et al., to Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA (Nov. 6, 2013), 
available at http://www.hpm.com/pdf/blog/FDA%20IND%20Connie%20Weaver%20letter.pdf.
89 See Sanders, supra note 87.
90 See fda, ind guidanCe for industry, supra note 82.
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have been instituted and their existence has been made public.” However, as noted by 
commentators, the FDA has still not defined “substantial,” and this subsection may 
inhibit manufacturers and researchers from pursuing research that studies the role of 
foods in preventing disease, improving health, or treating disease, because it may prevent 
them from selling the product as a food for general consumption rather than as a drug 
with a more limited distribution.91
D. Recommendations
In order to address concerns expressed by probiotic researchers and manufacturers, 
the FDA should adopt clear guidelines for when an IND is or is not required. We 
recommend, consistent with current law, that if proposed research is to support the 
development of a new drug, then an IND should be required. However, no IND should 
be required for research on probiotic products to evaluate the following claims: S/F 
claims, food for special dietary use claims, disease management claims for “medical 
foods” pursuant to the Orphan Drug Act Amendments of 1988, or health claims (disease 
risk reduction claims) as provided for in the Nutrition Labeling and Education Act 
(NLEA) of 1990. The FDA should base assignment of a substance or microorganism 
to a particular category on the claims made, rather than on the nature of the research 
supporting those claims, e.g., the endpoints of the study. Furthermore, the S/F effects 
of a probiotic should be able to be investigated in a diseased population without an 
IND if: a) the probiotic is marketed or intended to be marketed as a food (including 
medical foods and foods for special dietary use) or dietary supplement, and b) the study 
is being conducted to support an S/F or other non-drug claim. This assumes that the 
study will be conducted pursuant to the usual protections for study participants such 
as IRB approval and informed consent. In addition, no IND should be necessary for 
safety studies being conducted to support a GRAS determination or NDI submission. 
The concerns relating to research endpoints lead to several recommendations. First, 
research with disease outcomes should be allowed to substantiate non-drug claims 
without designating the product as a drug, as long as the effect of the product on healthy 
individuals is known. Moving forward, validated biomarkers for disease prevention in 
healthy populations are necessary, especially for the gut and immune system. Without 
these acceptable endpoints, companies may not be able to conduct useful clinical trials 
for non-drug claims. This is a problem in research generally, not just in probiotics 
research, but one that is particularly difficult for probiotics because many endpoints 
tested for probiotics do not have validated biomarkers. Furthermore, the FDA should 
encourage the study of acceptable ways to: 1) demonstrate modulation of a condition—
for example, cholesterol level—in healthy individuals without making a disease claim, 
and 2) measure homeostasis.
We further recommend that FDA adopt guidelines establishing an abbreviated IND 
process that would allow researchers, in certain situations, to bypass Phase 1 clinical 
safety studies.92 Probiotics would be eligible for such an abbreviated IND process only if 
91 Due to extensive concerns and comments raised about the guidance, on January 16, 2014, the FDA 
took the unusual step of announcing that the agency would reopen the comment period during which members 
of the public could submit comments on proposed guidance for an additional 60 days. See FDA to Reopen 
Comment Period on the Cosmetics and Food Portions of Its Guidance on Determining if Human Research 
Studies Require an Investigational New Drug Application, food & drug adMin. (Jan. 16, 2014), http://www.
fda.gov/Food/NewsEvents/ConstituentUpdates/ucm381474.htm. The comment period was only reopened 
for subsections of the final guidance that address the applicability of the IND regulations to clinical research 
studies involving cosmetics and foods (including dietary supplements). See 79 Fed. Reg. 7204-01 (Feb. 6, 
2014) (opening the comment period until Apr. 7, 2014).
92 See, e.g., Hoffmann et al., supra note 12, at 314.
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adequate evidence of safety in the target population at the desired use levels is available. 
Under this proposal, for probiotics in the abbreviated IND category: (1) the probiotic 
that is the subject of the abbreviated IND must be researched in the same dose and 
delivery system as the probiotic previously deemed to be safe (via the GRAS process 
or other approved process) so as not to raise a safety concern; and (2) if the sponsor 
wishes to conduct a study to support a therapeutic benefit for an at-risk population, then 
the FDA must make a determination if the available information on safety is suitable 
for this new target population.
The abbreviated IND process application would include an introductory statement 
and general investigational plan;93 a clinical study protocol for which IRB approval 
would be required; a summary of clinical safety data and/or in-market exposure data 
(e.g., material time and extent94); reference to GRAS specifications or a copy of the NDI 
notification95 as appropriate; documentation that the strain being investigated is GRAS 
or the subject of an NDI; and an FDA-approved certificate of analysis.96 
vi. whAt typeS oF product chArActerizAtion 
requirementS Are AppropriAte For probioticS?
A. Current Guidance and its Application to Probiotics
Characterization is used to identify products and to ensure that a product is what 
it claims to be—“[r]eliable identification by adequate methods confirms the identity 
of the strain in commercial use and is also necessary for proper labeling of products 
containing them.” 97 The issue of characterization is particularly important in relation 
to probiotics because, unlike most other regulated products, probiotics are living 
organisms and therefore change over time, making it more challenging to be certain of 
the characteristics of the product post-manufacture.
The FDA uses different characterization standards for the different categories 
of regulated products. According to our research, the agency has not set forth 
characterization requirements specifically for probiotics either at the research or 
93 Such a plan is described in 21 C.F.R. § 312.23(a)(3) (2013). 
94 The FDA uses “material time and extent” data to determine whether a drug can be included in the 
over-the-counter (OTC) drug monograph based on an analysis of whether the drug (or component of the drug) 
has been on the market to a sufficient extent over a sufficient period of time to meet the statutory test set 
forth in the guidance noted in this footnote. The regulations establish a two-part process. First, to determine 
whether a drug product is eligible to be considered for the OTC monograph system, certain information must 
be submitted in a time and extent application to show that a drug product (or component of the product) 
has been marketed as an OTC to a material extent and for a material time. Second, if the drug product is 
found eligible, the FDA publishes a notice of eligibility in the Federal Register that requests that interested 
persons submit data to demonstrate the safety and effectiveness of the drug product for its OTC use(s). See 
Center for drug evaluation & researCH, food & drug adMin., guidanCe for industry: tiMe and extent 
appliCations for nonpresCription drug produCts (Sept. 2011), available at http://www.fda.gov/downloads/
Drugs/.../Guidances/ucm078902.pdf. 
95 The FDA does not maintain a list of NDI-notified substances, but there are a number of subscription-
only databases of NDI-notified substances maintained by private organizations such as the American Herbal 
Products Association. See, e.g., NDI Database, AHPA, http://ndi.npicenter.com/ (last visited Feb. 10, 2014). 
96 The FDA has not published a formal definition of Certificate of Analysis (COA), but notes in the 
final rule relating to good manufacturing practices for dietary supplements that a COA is a “document, 
provided by the supplier of a component prior to or upon receipt of the component that documents certain 
characteristics and attributes of the component.” See 72 Fed. Reg. 34,752, 34,834 (June 25, 2007).
97 Célia Lucia Perreira et al., Probiotics: from Origin to Labeling from a European and Brazilian 
Perspective, in probiotiCs & HealtH ClaiMs, supra note 21, at 75, 79.
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manufacturing stage.98 However, as mentioned above, in 2012 the agency published 
guidance that sets forth requirements for chemistry, manufacturing, and controls (CMC) 
for early clinical trials using live biotherapeutic products (LBP).99 Without using the 
word “probiotic,” the language used in the guidance and its definition of LBP indicate 
that the FDA believes that probiotics fit within the LBP category.100 This is problematic 
as the characterization requirements in the LBP guidance may not be appropriate for 
probiotics, even if the probiotic meets the definition of a drug and falls squarely within 
the parameters of the guidance. The guidance provides that:
A description of the LBP’s drug substance, including its physical, chemical, 
or biological characteristics, must be included in the IND. A description of 
the drug substance should include the following: 
•	 Biological name and strain designations; 
•	 Original source of cells from which the drug substance was derived; 
•	 Culture/passage history of the strains; 
•	 If cells were obtained from a clinical specimen, a description of the 
clinical health of the donor(s), if known (merely noting procurement 
from a commercial provider is not adequate); 
•	 Summary of the phenotype and genotype of the product strains, with 
special attention to biological activity or genetic loci that may indicate 
activity or potency; and 
•	 Documentation and summary of modifications, if any, to the LBP, e.g., 
intentional introduction of foreign genes or mutations, along with details 
of the genetic construction. 
Characterization of an LBP must include a description of the acceptable 
limits and analytical methods used to assure the identity, strength, quality, 
and purity of the drug substance.101 
These requirements are not adequately customized for probiotics. Specifically, the 
current LBP guidance requires a summary of the phenotype or genotype of the strain 
with specific attention to the genetic loci that may indicate activity or potency. It is very 
difficult to pinpoint the genetic loci for probiotics, especially in early clinical trials. 
Furthermore, the guidance refers to genotypic methods that are inadequate and outdated. 
Perreira et al. described the evolution of characterization techniques:
During the last few years molecular techniques have replaced or 
complemented traditional phenotypic methods. DNA-DNA hybridization is 
98 However, in January 2012, the U.S. Pharmacopoeia (USP) released draft standards —Microbial Food 
Cultures Including Probiotics—that detail the essential quality specifications, intended uses in food, safety 
considerations, regulatory status, and purity of probiotics. The standards will be incorporated into the Food 
Chemicals Codex. News Release, Critical Quality Considerations for Probiotics and Other Microbial Food 
Cultures Offered in New Draft FCC Standards (Jan. 3, 2012), available at http://us.vocuspr.com/Newsroom/
ViewAttachment.aspx?SiteName=USPharm&Entity=PRAsset&AttachmentType=F&EntityID=109245&A
ttachmentID=89eaa2c7-02d6-453f-b16c-94e7d2592e4a. While still untested, these new standards may be 
helpful in the characterization of probiotics. 
99 See FDA, guidanCe for industry, supra note 44. 
100 According to the guidance, “[a live biotherapeutic product] LBP . . . is a biological product that: 
1) contains live microorganisms, such as bacteria; 2) is applicable to the prevention, treatment, or cure of a 
disease or condition of human beings; and 3) is not a vaccine.” Id. at 3.
101 Id. at 7-8.
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the current gold standard for determination of bacterial identification, with 
two strains being considered to belong to the same species if their DNA-
DNA relatedness is 70% or more. However, due to the difficulties associated 
with this technique, and the need of expertise not normally present in the 
food industry, phylogenetically based approaches such as sequence analysis 
of the 16S rRNA gene are currently the most commonly used methods for 
bacterial species identification. In general, microorganisms sharing a 16S 
rRNA gene homology higher than 97% are considered members of the 
same species.102
A specific and unique application of probiotics—fecal microbiota transplantation (FT) 
or fecal transplant—is useful to understand the complexity of characterizing probiotics. 
FT is an existing treatment that involves the process of transplantation of fecal material 
(including the microbiota) from a healthy individual into a recipient as a treatment for 
patients suffering from various severe intestinal disorders such as Clostridium difficile 
infection. If the stool contents could be made into a tablet, capsule or suppository for 
ingestion,103 it would raise the question of whether it would, or could, meet the FDA 
standards for characterization. The current standards would be difficult to meet because 
it would likely be impossible to identify and characterize to current standards all the 
microbes in the tablet, capsule or suppository, therefore causing the “microbial limit” 
test in the guidance to be exceeded. Furthermore, the chemical and microbiological 
components of the formulation would clearly vary from batch to batch and therefore 
run afoul of the requirement for consistency in product composition. In a recent article, 
Olle discusses the challenges stating that: 
[a]lthough CBER’s [LBP] guidelines seem clear for products based on 
defined compositions of live organisms, it is still unclear how these 
guidelines will be applied to FT. Technically, FT meets the definition of 
LBPs, but in practice, the guidelines are ill-suited to this type of product. 
Reproducibly obtaining well-characterized CMP-grade materials for trials 
according to the criteria outlined by CBER would require a titanic effort 
outside the reach of current technologies (e.g., meeting the microbial test 
limits, would not be possible.)104
The FDA acknowledged the inadequacy of current IND requirements to evaluate 
FTs when it did a turnaround in 2013 regarding the need to seek FDA approval prior to 
performing the treatment. In May 2013, FDA announced that physicians performing 
FTs would need to seek an IND in advance of using the procedure on patients.105 
FDA justified this position based on the concept that fecal microbiota falls within the 
agency’s definition of a biologic and therefore requires an IND before it can be used 
102 See Perreira et al., supra note 97, at 79.
103 Current FT delivery methods include endoscopic procedures and enemas. Faith Rohlke & Neil 
Stollman, Fecal Microbiota Transplantation in Relapsing Clostridium Difficile Infection, 5 tHerapeutiC 
advanCes in gastroenterology 403 (2012). 
104 Olle, supra note 8, at 310.
105 See Letter from Karen Midthun, Dir., Ctr. for Biologics Evaluation and Research, to Dr. C. Richard 
Boland et al., Am. Gastroenterological Soc’y (Apr. 25, 2013), available at http://highroadsolution.com/file_
upload_2/files/fda+response+letter+to+fmt+inquiry.pdf (noting in response to inquiry by gastroenterologists 
that fecal microbiota for transplantation fell within the definition of drug and “would be an Investigational 
New Drug for which an Investigational New Drug application must be submitted”); see also Joyce Frieden, 
FDA Backs Down on Fecal Transplant Rules, Medpage today, July 22, 2013, http://www.medpagetoday.
com/Gastroenterology/GeneralGastroenterology/40628. 
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in humans.106 However, in guidance released in July 2013, FDA acknowledged that 
applying IND requirements might make FT unavailable to patients who could benefit 
from the procedure and therefore agreed to “to exercise enforcement discretion regarding 
the IND requirements” for the use of FT to treat C. difficile infection not responding 
to standard therapies.107 FDA also noted that an “alternative regulatory approach” may 
be needed to ensure the widespread availability of FT.108 
B. Recommendations
In terms of the test for microbial burden, guidance relating to probiotics should 
specify what kind of assay is required. Recently, “the development of high-throughput 
sequencing technologies has enormously increased sequencing capability, significantly 
reducing sequencing costs.”109 Given these new techniques and the reduction in their 
costs, current genome sequencing technology should be required, as it allows for whole 
genome analysis and could serve as the standard for characterization.
In terms of developing characterization requirements for probiotics, the FDA should 
consider the following suggestions:
•	 Characterization requirements should be developed for probiotics in foods and 
dietary supplements, as well as probiotics in drugs. Differences between the 
requirements for both groups should be clearly set forth by the FDA.
•	 The agency should specifically address the seminal bacterial features that determine 
whether the resulting probiotic is the same or different from previous products. The 
FDA will also need to consider whether these key features should be different for 
probiotics used for oral versus non-oral use (e.g., dietary supplement, food, medical 
food, or drug use, versus use of a probiotic in conjunction with a medical device). 
•	 Characterization standards must be flexible enough to encompass new technologies 
and must be specific enough to allow for proper/precise identification of strains. 
•	 The microorganism added to make a probiotic should be deposited in an 
independent reference culture collection as a means of assuring consistency 
between the product taken by consumers and the product as marketed.
•	 The USP draft standards for products containing probiotics could be the basis 
of a broader standard focused on probiotic ingredients in general, versus solely 
those in foods.
•	 All products should have a certificate of analysis on file for each lot produced, 
done by a reputable company, certifying what organisms are present, and in what 
quantity. It should also include testing for potential contaminants.110 
106 See Frieden, supra note 105.
107 See u.s. food & drug adMin., guidanCe for industry: enforCeMent poliCy regarding 
investigational neW drug reQuireMents for use of feCal MiCrobiota for transplantation to treat 
ClostridiuM diffiCile infeCtion not responsive to standard tHerapies 2 (July 2013), available at http://
www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/
Vaccines/UCM361393.pdf.
108 Id. See also Mark B. Smith et al., How to Regulate Faecal Transplants, 506 Nature 290 (2014) 
(noting that “the long-term status of [FT] for C. difficile infection is unresolved, and regulatory policy is 
complicating research into the exploration of FMT for other conditions, such as inflammatory bowel diseases 
or obesity.”).
109 Perreira et al., supra note 97, at 81.
110 See Patricia Hibberd, Recommendations for Modifications to the FDA Regulatory Framework for 
Probiotics (on file with the authors).
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•	 Regulators should clarify the degree to which probiotics are characterized in 
different contexts, i.e., in labeling, NDI notification, or development of good 
manufacturing practices.111
vii. Are current cLAim reguLAtionS AppropriAte  
For probioticS And, iF not, how might they  
be improved?
A. Jurisdiction over Claims
For health-related products, both the FDA and the FTC regulate what manufacturers 
can say about a product. Furthermore, the claims a manufacturer makes about a product 
also relate to how that product is regulated by the FDA, e.g., products making what 
the FDA considers to be drug claims are required to go through the drug approval 
process. Because different FDA regulatory categories require vastly different degrees 
of scientific substantiation (and therefore investment) for claims, the issue of how 
claims are regulated is very complex and often controversial. As some probiotics do 
not squarely fit into current FDA product categories, the issue of claims regulation is 
further complicated and unclear. 
The FDA regulates claims that appear in labeling of prescription and over-the-counter 
(OTC) drugs, medical devices, dietary supplements, cosmetics, and food, and claims 
made in advertising of prescription drugs. Labeling includes any “text or graphics” on 
websites where these products are sold.112 The FTC regulates claims made in advertising 
of OTC drugs, foods, dietary supplements, non-restricted medical devices, and cosmetics 
(including TV, radio, internet and print ads). 
B. FDA Claims Regulation
Products under the FDA’s jurisdiction are subject to an array of differing regulatory 
requirements regarding permissible product claims. Claims describing the effect of a 
substance on the diagnosis, treatment, mitigation, cure or prevention of disease are 
considered drug claims.113 These claims must be approved by FDA prior to marketing 
the drug. An example of a drug claim is that a product “reduces the pain and stiffness 
associated with arthritis.” 
Foods and dietary substances may make four types of claims: (1) structure/function 
(S/F); (2) nutrient content; (3) health; and (4) qualified health claims. S/F claims 
describe the role of a nutrient or dietary ingredient intended to affect normal structure 
or function of the body in humans. There is no preapproval required for these claims; 
however, the manufacturer is responsible for ensuring the accuracy and truthfulness 
of these claims, and a dietary supplement manufacturer must notify the FDA within 
30 days of marketing a dietary supplement with an S/F claim. In addition, S/F claims 
made by dietary supplement manufacturers must bear the following disclaimer: “This 
statement has not been evaluated by the Food and Drug Administration. This product 
is not intended to diagnose, treat, cure or prevent any disease.”114 An example of an 
111 Note that some of these recommendations are already in place for certain NIH-funded studies.
112 See 21 CFR § 1.3 (2013) (“Label means any display of written, printed, or graphic matter,” applicable 
to all FDA-regulated products).
113 An exception to this is health claims, i.e., claims for reduction of risk of disease (which are a category 
of prevention claims). Health claims can be made for foods and dietary supplements. See notes 118-121 infra.
114 21 U.S.C. § 343(r)(6)(c) (2012).
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S/F claim is: “Helps maintain normal cholesterol levels.”115 Nutrient content claims 
characterize nutrient levels. An example is “this product contains 40% omega-3 fatty 
acids, 10 mg. per cap.”116 
Health claims describe the effect of a product on the reduction of risk of disease in 
a healthy or at-risk population. Although “reduction of risk of disease” might also be 
considered a prevention claim, which would otherwise be considered a drug claim, under 
the NLEA, Congress carved out an allowance for foods and dietary supplements wishing 
to make reduction of risk of disease claims. 117 Health claims for foods and dietary 
supplements may be approved by FDA if there is “significant scientific agreement” that 
the claimed relationship between the nutritional product and reduction of risk of disease 
is true OR on the basis of an authoritative statement by a U.S. government scientific 
body.118 Under the Food and Drug Administration Modernization Act of 1997 (FDAMA), 
manufacturers may also make health claims for food (but not dietary supplements) if 
the health claim is based on an authoritative statement from a scientific body of the 
U.S. Government or the National Academy of Sciences.119
Qualified health claims require less than significant scientific agreement and must 
be accompanied by a disclaimer or qualifier explaining the level of scientific evidence 
support for the claim.120 Manufacturers wishing to use a qualified health claim must 
115 Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on 
the Structure or Function of the Body, 65 Fed. Reg. 1000 (Jan. 6, 2000) (to be codified at 21 C.F.R. pt. 101).
116 For a full description of nutrient content claims, see Claims that Can be Made for Conventional 
Foods and Dietary Supplements, food & drug adMin. (Sept. 2003), http://www.fda.gov/food/
ingredientspackaginglabeling/labelingnutrition/ucm111447.htm. 
117 See Pub. L. No. 101-535, 104 Stat. 2353 (codified as amended at 21 U.S.C. §§ 301, 321, 337, 
343, 371).
118 The mechanism for approval for health claims was established by the NLEA and DSHEA. A finding 
of significant scientific agreement by the FDA requires the agency’s best judgment as to whether qualified 
experts would likely agree that the scientific evidence supports the substance/disease relationship that is 
the subject of the proposed health claim. See Guidance for Industry: Evidence-Based Review System for 
the Scientific Evaluation of Health Claims, food & drug adMin. (Jan. 2009), http://www.fda.gov/Food/
GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm073332.htm. An 
example of an approved health claim is “Use of calcium in the diet on a regular basis may help to reduce the risk 
of osteoporosis.” The FDA has approved very few health claims; none for probiotics. A list of approved health 
claims appears at Health Claims Meeting Significant Scientific Agreement, food & drug adMin., http://www.
fda.gov/food/ingredientspackaginglabeling/labelingnutrition/ucm2006876.htm#Approved_Health_Claims 
(last visited Feb. 10, 2014).
119 Pub. L. No. 105-115, Sec. 303, 111 Stat. 2296, 2357 (codified at 21 U.S.C. § 343(r)(3)). FDAMA 
specifically lists the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention 
(CDC) as scientific bodies that would satisfy the statutory requirement. FDA has also stated that the Surgeon 
General within the Department of Health and Human Services, the Food and Nutrition Service, the Food 
Safety and Inspection Service, and the Agricultural Research Service within the Department of Agriculture, 
may serve as qualified “scientific bodies.” See Guidance for Industry: Notification of a Health Claim or 
Nutrient Content Claim Based on an Authoritative Statement of a Scientific Body, food & drug adMin. 
(July 11, 1998), http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/
LabelingNutrition/ucm056975.htm. 
120 Qualified health claims (QHCs) were created by judicial rulings over the past decade and a half. In 
Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999), the plaintiffs challenged the FDA’s general health claims 
regulations for dietary supplements and the FDA’s decision not to authorize health claims for four specific 
substance/disease relationships. The U.S. Court of Appeals for the D.C. Circuit held that the First Amendment 
does not permit the FDA to reject health claims that the agency determines to be potentially misleading, 
unless the agency also reasonably determines that no disclaimer would eliminate the potential deception. 
Id. at 658-60. Based on this ruling, the FDA created the QHC. An example of a QHC is the following: “One 
small study suggests that chromium picolinate may reduce the risk of insulin resistance . . . FDA concludes, 
however, that the existence of such a relationship . . . is highly uncertain.” There are currently no qualified 
health claims for any probiotic product.
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file a petition with the FDA within 30 days of marketing a product.121 The FDA may or 
may not issue a letter of enforcement discretion during that time.122 
A unique category of foods, i.e., medical foods, has separate regulations for claims. 
Medical food claims are exempt from the requirement to bear nutrition labeling123 
and from the health claim and drug requirements that attend the mention of a disease 
relationship on a product label124 if the product is specially formulated and processed 
for partial or exclusive feeding of a patient orally or by enteral tube; intended for dietary 
management of a patient when it cannot be achieved by modifying the normal diet (e.g., 
chronic medical needs; limited/impaired capacity to ingest, digest, etc.; other special 
medically determined nutrient needs); providing nutritional support to manage unique 
nutrient needs resulting from a specific disease/condition (per medical evaluation); 
intended for use only under medical supervision; and intended only for patients receiving 
active/ongoing medical supervision.125
C. FDA Labeling Requirements
The FDA has the responsibility for administering federal food labeling requirements 
in accordance with the FDCA.126 The Act prohibits labeling that, among other things, 
is false or misleading or that fails to list the amounts of certain ingredients.127 Within 
the FDA, CFSAN’s “Office of Nutrition, Labeling and Dietary Supplements publishes 
regulations and guidance on food labeling” (including conventional food, dietary 
supplements, infant formula and medical foods) and “provides policy interpretations 
for overseeing compliance” with the relevant statutes and regulations.128 The Nutrition 
Labeling and Education Act (NLEA) of 1990129 “requires most foods to bear nutrition 
labeling and requires food labels that bear nutrient content claims and certain health 
messages to comply with specific requirements.”130 The FDA stipulates that all food 
products must have a principal display panel that contains the statement of identity 
121 21 U.S.C. § 343(r)(6)(c) (2012). 
122 The FDA has broad regulatory authority and enforcement discretion in the area of qualified health 
claims. Although premarket approval of these claims is not required, a manufacturer may file a petition in 
advance of making a qualified health claim. In response to a petition, the agency may choose to exercise its 
enforcement authority in this area. One available measure is a “letter of enforcement discretion,” in which the 
FDA informs a manufacturer of what it can and cannot do in relation to a specific claim. See, e.g., Qualified 
Health Claims: Letter of Enforcement Discretion – Chromium Picolinate and Insulin Resistance, food & 
drug adMin. (Aug. 25, 2005), http://www.fda.gov/food/ingredientspackaginglabeling/labelingnutrition/
ucm073017.htm. 
123 See 21 C.F.R. § 101.9(j)(14) (2013).
124 See 21 C.F.R. § 101.14(f) (2013).
125 See 21 C.F.R. § 101.9(j)(8) (2013). All other food labeling requirements (e.g., statement of identity, 
listing of ingredients, declaration of net weight, nutrient content claim restrictions, etc.) and all food safety 
standards apply to medical foods. See food & drug adMin., draft guidanCe for industry: freQuently 
asked Questions about MediCal foods 5-6 (2d ed. 2013), available at http://www.fda.gov/downloads/Food/
GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/MedicalFoods/UCM362995.pdf.
126 15 U.S.C. § 1453 (2012).
127 15 U.S.C. § 1452 (2012).
128 u.s. gov’t aCCountability offiCe, gao-08-597, food labeling: fda needs to better leverage 
resourCes, iMprove oversigHt, and effeCtively use available data to Help ConsuMers seleCt HealtHy 
foods 2 (2008), available at http://www.gao.gov/assets/290/280466.pdf.
129 Pub. L. No. 101-535, 104 Stat. 2353 (codified as amended at 21 U.S.C. § 301, 321, 337, 343, 371).
130 See food & drug adMin., guidanCe for industry: a food labeling guide 4 (Sept. 1994, rev. Apr. 
2008, rev. Oct. 2009, rev. Jan. 2013), available at http://www.fda.gov/downloads/Food/GuidanceRegulation/
UCM265446.pdf.
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(name of the food) and the net quantity statement (amount of product).131 Food labels 
must meet FDA standards but do not require preapproval.132 
Labeling of dietary supplements is covered by DSHEA. DSHEA amended the FDCA 
by defining “dietary supplements” and adding specific labeling requirements for them, 
as well as optional labeling statements. Labeling requirements for dietary supplements 
include: 1) a statement of the product’s identity, i.e., the name of the supplement; 2) a 
net quantity of contents statement (or the amount of the dietary supplement); 3) nutrition 
labeling; 4) an ingredient list, and 5) the name and place of business of the manufacturer, 
packer, or distributor. Currently, probiotic food and dietary supplement manufacturers 
do not have to specify on their product labels the strains they use in probiotic products 
or specify the number of live microbes of each strain that the products deliver through 
the end of shelf life. 
When FDA approves a New Drug Application, that approval includes the drug 
labeling.133 This preapproval mechanism gives the FDA greater control over the labeling 
than it has for foods and dietary supplements. Under the FDA’s prescription drug labeling 
guidelines, specific information must be included on the label or a package insert. A 
drug label must provide information about the safe and effective use of the drug that is 
informative and accurate; contain no promotional, false, or misleading claim; and make 
no implied claims or suggestions for use if evidence of safety or effectiveness is lacking. 
D. Impact of FDA Claim Regulation on Probiotic Products
1. Confusion among Health Claims, Structure-Function Claims 
and Drug Claims
An issue for probiotic manufacturers is what claims can be made about probiotic 
products and the substantiation required for each type of claim. Because most probiotics 
appear in foods and dietary supplements, there are significant limits on what claims 
can be made without crossing the line into the heavily regulated drug arena. Moreover, 
because consumers do not perceive health claims as better or more substantive than 
S/F claims,134 there appears to be little return on investment for a food company to go 
through the costly and lengthy process to gain an approved health claim. Anecdotally, 
manufacturers are reluctant to avail themselves of the process in place for approval of 
authorized health claims because of the amount of time and resources such a process 
takes and a lack of understanding of the FDA’s guidance in this area. This is borne out 
by the fact that the FDA has only approved 12 health claims by regulation to date.135 
S/F claims are currently used by a number of probiotic food and dietary supplement 
manufacturers because they require less evidence to substantiate than other types of 
131 The statement of identity is the name of the product by law or regulation. Ingredients must be listed 
in descending order by predominance and weight. The nutrition facts must appear on each product, including 
total calories, fat, carbohydrates, protein and fiber. “Trace ingredients” must be listed if the trace ingredient is 
present in a significant amount and has a function in the finished food. If a substance is an incidental additive 
and has no function or technical effect in the finished product, then it need not be declared on the label. Id. 
at 17-18.
132 To determine the nutrient levels in foods, however, companies may develop or use databases, and 
the databases may be submitted voluntarily to the FDA for review. Id. at 31. 
133 In the case of products subject to an OTC monograph, described infra note 175 and accompanying 
text, because the monograph includes approved claims and approved labeling, these products can enter the 
market without preapproval by the FDA if the claims and labels are allowed by the monograph.
134 gen. aCCounting offiCe, rCed-00-156, iMproveMents needed in overseeing tHe safety of dietary 
suppleMents and ‘funCtional foods’ (2000), available at http://www.gao.gov/assets/230/229289.pdf.
135 See Health Claims Meeting Significant Scientific Agreement, supra note 118. 
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claims and do not require preapproval by the FDA. However, when and how S/F claims 
can be made is complicated and sometimes difficult to discern. This confusion is in 
part a result of the origin of this type of claim. As stated above, the statutory definition 
of a drug in the FDCA includes an article intended to diagnose, cure, mitigate, treat or 
prevent disease.136 Also included in the FDCA definition is the concept that drugs are 
“articles (other than food) intended to affect the structure or any function of the body 
of man or other animals.”137 The phrase “other than food” implicitly recognizes that a 
food or food ingredient can affect the structure or function of the body without thereby 
becoming a drug. This recognition is the basis for the S/F claim.138 
Although the FDA has issued detailed regulations and guidance attempting to 
differentiate between S/F claims for foods and dietary supplements and drug claims 
that may not be made without prior FDA approval,139 the guidance has not always 
been helpful. It is often difficult to distinguish drug claims from S/F claims for dietary 
supplements and foods. Examples of the difficulty in discerning where a claim falls 
are illustrated in Table 1, below. 
tAbLe 1: diFFerenceS between Structure/Function And drug cLAimS140
Structure/Function Claim  
(no prior approval needed)
Drug Claim (approval needed)
Helps maintain normal cholesterol levels Lowers cholesterol
Maintains healthy lung function Maintains healthy lung function in smokers
Provides relief of occasional constipation Provides relief of chronic constipation
Suppresses appetite to aid weight loss Suppresses appetite to treat obesity
Supports the immune system Supports the body’s antiviral capabilities
2. Difficulty Conducting Research for Structure/Function Claims
Despite the fact that S/F claims have typically been considered less regulated and thus 
easier to make, some industry representatives believe that it is increasingly difficult to 
conduct research to make S/F claims due to the narrow range of acceptable endpoints 
for S/F claims. Under the definition of a drug in the FDCA, food labeling is permitted 
to include claims relating to the intended effect on the structure or function of the 
human body without classifying the product as a drug.141 Recognizing this, in DSHEA, 
Congress explicitly authorized claims for dietary supplements that “describe[] the role 
of a nutrient or dietary ingredient . . . to affect the structure or function in humans [and] 
characterize the documented mechanism by which a nutrient or dietary ingredient acts 
to maintain such structure or function.”142 In promulgating regulations under DSHEA, 
136 FDCA, sec. 201(g)(1) (codified at 21 U.S.C. § 321(g)).
137 Id.
138 See supra notes 86-88 and accompanying text.
139 Guidance for Industry: Structure/Function Claims, Small Entity Compliance Guide, food & drug adMin. 
(Jan. 9, 2002), http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/
DietarySupplements/ucm103340.htm; Claims That Can Be Made for Conventional Foods and Dietary 
Supplements, food & drug adMin. (Sept. 2003), http://www.fda.gov/Food/IngredientsPackagingLabeling/
LabelingNutrition/ucm111447.htm.
140 Center for Science in the Public Interest, Claims Crazy, Which Can You Believe?, nutrition aCtion 
HealtHletter, June 2003, http://www.cspinet.org/nah/06_03/claim.pdf.
141 FDCA, sec. 201(g)(1) (codified at 21 U.S.C. § 321(g)).
142 Dietary Supplement Health & Education Act of 1994 (DSHEA), FDCA Sec. 413(c), 21 U.S.C. 
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however, the FDA stated that an S/F claim will be considered a drug claim if it indirectly 
or impliedly relates to disease prevention or amelioration.143 Some have argued that in 
doing this, the FDA overreached its statutory authority under DSHEA.144 This is another 
area in which more clarity is required, especially given the fact that any prohibition on 
“implied” statements requires judgment calls that probiotic manufacturers may not be 
able or willing to make. 
3. Prevention versus Risk Reduction Claims
A complex area of the law that impacts regulation of probiotics is the difference 
between a disease prevention claim and a risk reduction claim and how these claims may 
be handled differently by the FTC and the FDA. The subtle difference between a disease 
prevention claim and a risk reduction claim is important because disease prevention 
claims are considered drug claims but risk reduction claims are permitted for foods and 
dietary supplements under the Nutrition Labeling and Education Act (NLEA) of 1990. 
As the law stands now, a permissible health claim can suggest that a food reduces 
the risk of developing a disease, but it becomes a drug claim, rendering the product an 
unapproved drug, if it suggests mitigation, cure or treatment of an existing disease. With 
the exception of classical nutrient deficiency diseases, a claim that a food may prevent 
future disease may also render a product an unapproved drug. For example, the express 
claim that a food product prevents cardiovascular disease (CVD) is a drug claim, while 
the express claim that a food reduces the risk of development of CVD is a health claim 
if it is authorized by the Secretary under the provisions of the NLEA. This distinction 
allows food manufacturers to, in effect, make reduction of risk claims but be subject 
to a lower standard of evidence than that imposed on drug manufacturers wishing to 
make prevention or reduction of risk claims. This might happen when, for example, 
a drug manufacturer has an existing product that already makes a claim regarding the 
product’s ability to mitigate, cure or treat a disease and the manufacturer wants to add a 
prevention or risk reduction claim. Because the product is already in the drug category, 
the manufacturer would have to meet the claim substantiation standard for a prevention 
claim (rather than the arguably lower standard that a food would have to meet to make 
a reduction of risk of disease claim).145
Different standards for claims and what claims mean is complicated for manufacturers, 
but different types of claims also make it challenging for consumers to make educated 
choices at the supermarket. This difficulty is exacerbated by the fact that many S/F 
claims are based on small, preliminary unpublished studies or studies conducted on 
diseased populations rather than healthy individuals. Although the law requires claims to 
be truthful and based on sufficient evidence, inevitably some ambiguous or misleading 
claims reach the marketplace. Furthermore, many S/F claims are based on different 
formulations than what is actually in the product or on studies that look at biomarkers 
of unknown significance and often do not disclose that research shows the product 
does not work as claimed.
§ 350(b) (2012).
143 Guidance for Industry: Structure/Function Claims, Small Entity Compliance Guide, supra note 139.
144 See, e.g., Dietary Supplement Health and Education Act: Is the FDA Trying to Change the Intent 
of Congress?, Oversight Hearing Before the H. Comm. on Government Reform, 106th Cong. (1999), quoted 
in William D. McCants, Take a Label Claim, and Pay Me in the Morning: A Challenge to FDA’s Argument 
that its Final Rule (Jan. 2000) on Structure/Function Claims for Dietary Supplements Does Not Constitute a 
Compensable Regulatory Taking Under the Fifth Amendment, Harv. legal eleC. doCuMent arCHive (leda) 
paper (Mar. 2000), available at http://dash.harvard.edu/bitstream/handle/1/8965592/McCants,_William_D..
html?sequence=1. 
145 Richard L. Cleland (personal communication, December 24, 2013).
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4. Probiotics as Medical Foods
The medical foods category has been mentioned as appropriate for certain probiotics 
and probiotic claims. However, the FDA advises in its guidance relating to medical 
foods that it considers the statutory definition of medical foods to narrowly constrain 
the types of products that fit within this category of food. The FDA warning letters for 
purported medical foods have focused primarily on the absence of distinctive nutritional 
requirements for the disease or condition for which the product is marketed, as well as 
unlawful marketing practices and illegal drug claims. Given the FDA’s narrow view 
of this category, without modification it is likely not a useful avenue for regulation for 
probiotics outside of those probiotics that currently fit into the regulations noted above.
E. FTC Regulation of Advertising Claims
The FTC rules regarding substantiation for health-related product claims are different 
from those of the FDA. Section 5 of the FTC Act prohibits “unfair or deceptive acts 
or practices in or affecting commerce,” 146 and Section 12 of the FTC Act prohibits 
disseminating or causing the dissemination of a false advertisement in commerce for 
the purpose of inducing, or that is likely to induce, the purchase of any food, drug, 
device, service, or cosmetic.147 
Manufacturers must have substantiation for objective product claims they make in 
advertisements. Under FTC law, making objective claims without a reasonable basis 
is a deceptive practice, and advertising claims made for a food, dietary supplement, 
drug, cosmetic or service without a reasonable basis for the claim constitutes false 
advertising.148 Determining the level of substantiation required to establish a reasonable 
basis for a claim is a complicated process requiring consideration of a number of relevant 
factors, including:
•	 the type of claim (health or safety claim)
•	 the product 
•	 the consequences of a false claim
•	 the benefits of a truthful claim
•	 the cost of developing substantiation for the claim
•	 the amount of substantiation experts in the field believe is reasonable.149
These principles apply to foods, dietary supplements, and drugs and claims that 
would be considered by the FDA to be S/F, health claims, qualified health claims or 
146 In terms of advertising, an advertisement is deceptive if it contains a representation or omission of 
fact that is likely to mislead a consumer acting reasonably under the circumstances, and that representation is 
material to a consumer’s purchasing decision. Deceptive advertisements are those that include false claims, 
fail to disclose material facts, or make unsubstantiated claims. In determining if an advertisement meets 
FTC requirements, the FTC interprets them from the perspective of a reasonable consumer in the target 
audience. As advertisements may have more than one reasonable interpretation, where an ad conveys more 
than one meaning, only one of which is misleading, a seller is liable for the misleading interpretation even if 
non-misleading interpretations are possible. An advertisement will be considered misleading if a significant 
number of reasonable consumers, which can be as low as ten percent, believe the misleading claim. Sec. 5 
of the Federal Trade Commission Act (codified at 15 U.S.C. § 45).
147 15 U.S.C. § 52 (2012). For more information about FTC regulation of health claims, see online 
webinar by Working Group Member Richard Cleland (Bureau of Consumer Protection, Federal Trade 
Commission) prepared for the Working Group at http://www.law.umaryland.edu/programs/health/events/
probiotics/claims_webinars.html.
148 FTC Policy Statement Regarding Advertising Substantiation, Appended to Thompson Med. Co., 
104 F.T.C. 648, 839 (1984), aff’d, 791 F.2d 189 (D.C. Cir. 1986), available at http://www.ftc.gov/bcp/guides/
ad3subst.htm.
149 Id.
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drug claims.150 For all of these health-related claims, the FTC requires substantiation 
by competent and reliable scientific evidence that is sufficient to satisfy the relevant 
scientific community that the claim is true. The evidence can consist of tests, analyses, 
research, or studies that have been conducted and evaluated in an objective manner 
by qualified persons and are generally accepted in the profession to yield accurate and 
reliable results.151 The supporting evidence must be sufficient in quality and quantity, 
when considered in light of the entire body of relevant and reliable scientific evidence, 
to substantiate that the representation is true. It appears from recent FTC enforcement 
activity that to meet this standard for claims that the FTC considers therapeutic (claims 
that a drug, food, or dietary supplement will treat, cure, or mitigate a health-related 
problem), at least two randomized clinical trials are required.152 For claims that relate 
to prevention or reduction of risk of a health-related problem, the FTC has allowed 
evidence other than randomized clinical trials to support such a claim, depending on 
the claim and the level of substantiation that experts in the field would generally require 
for such a claim. 
In general, the FTC gives great deference to an FDA determination of whether there 
is adequate support for a health claim.153 Nonetheless, the FTC’s Enforcement Policy 
Statement on Food Advertising notes that there may be certain limited instances when 
a carefully qualified health claim in advertising may be permissible under FTC law, in 
circumstances where it has not been authorized for labeling by the FDA.154 
An area of concern in relation to FTC regulation of probiotics is the degree of 
substantiation that is required to make health-related claims. Manufacturers could run 
into trouble with FTC regulators for using studies that the FTC considers inadequate 
to support the claim at issue, in that the study related to a different product, different 
dosage, different target population, or inappropriate endpoint for the claim.155 
While the distinction between disease prevention and risk reduction claims has been 
largely settled in the context of the FDA oversight of claims, the distinction between 
prevention and reduction of risk claims is less clear under the FTC Act. NLEA did 
not amend the FTC Act, and therefore the FTC does not make a distinction between 
reduction of risk of disease claims and prevention claims. Either claim must have a 
reasonable basis for substantiation, which has typically been less than the evidence 
required for therapeutic claims. The FTC has stated in opinions that this requires 
objective tests and studies or other evidence considered valid by professionals with 
expertise in the relevant area, “using procedures generally accepted in the profession 
150 See Memorandum of Understanding Between the Federal Trade Commission and the Food 
and Drug Administration, MOU 225-71-8003 (1971), available at http://www.fda.gov/AboutFDA/
PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMOUs/ucm115791.htm.
151 bureau of ConsuMer proteCtion, FTC, dietary suppleMents: an advertising guide for industry 
(2001), available at http://business.ftc.gov/sites/default/files/pdf/bus09-dietary-supplements-advertising-
guide-industry.pdf.
152 Note that S/F claims are not considered therapeutic claims by the FTC but rather fall into the 
category of health-related claims that require substantiation by competent and reliable scientific evidence 
that is sufficient to satisfy the relevant scientific community that the claim is true. See Heimbach, supra note 
18, at S123.
153 bureau of ConsuMer proteCtion, supra note 151. The FDA and FTC work under a memorandum 
of understanding that sets forth their respective responsibilities for “preventing injury and deception of the 
consumer.” See Memorandum of Understanding, supra note 150. 
154 See Enforcement Policy Statement on Food Advertising, fed. trade CoMM’n (May 1994), http://
www.ftc.gov/bcp/policystmt/ad-food.shtm. 
155 See bureau of ConsuMer proteCtion, supra note 151.
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to yield accurate and reliable results.”156 The standard allows for much flexibility on 
the part of the FTC and generally requires differing levels of evidence for different 
types of claims. There is no fixed formula for the number or type of studies required, 
sample size or study duration. Historically, the FTC considered the costs and benefits of 
efforts at substantiating claims, e.g., clinical trials and other human studies. The agency 
frequently defers to experts for their opinion. 
The FTC has not historically followed the FDA’s approach to regulation of health 
claims.157 However, that practice may be changing as evidenced by two actions against 
probiotic food manufacturers. In an action instigated by FTC against Nestlé Healthcare 
Nutrition (HCN) in 2010, the FTC alleged that Nestlé HCN made false claims in 
television, magazine, and print ads about its probiotic product BOOST Kid Essentials 
when the company claimed that the product prevents upper respiratory tract infections 
in children, protects against colds and flu by strengthening the immune system, and 
reduces absences from daycare or school due to illness.158 These statements, according to 
the FTC, went beyond simply claiming increased immunity to claiming that the product 
would prevent children from getting sick—a stronger claim that lacked substantiation. 
Nestlé HCN agreed to a consent order that was signed in May, 2010.159 The consent 
order prohibited Nestlé HCN from making claims that a product prevents or reduces 
the risk of upper respiratory tract infections (URTIs) “unless the FDA has issued a 
regulation authorizing the claim based on a finding that there is significant scientific 
agreement among experts qualified by scientific training and experience to evaluate 
such claims, considering the totality of publicly available scientific evidence.”160 The 
FTC considers this “significant scientific agreement” standard to be what “experts in 
the field of diet-disease relationships would consider reasonable substantiation for an 
unqualified health claim.”161 Going beyond the FTC Enforcement Policy Statement, 
the FTC required Nestlé HCN to obtain FDA preapproval before it could make a 
URTI risk-reduction claim for its products, because this preapproval would “facilitate 
compliance with the order.” 
As to Nestlé HCN’s claims that BOOST reduces children’s absences from daycare 
and school due to illness, the FTC determined that “competent and reliable scientific 
evidence” means “at least two adequate and well-controlled human clinical studies of 
the product, or of an essentially equivalent product, conducted by different researchers, 
independently of each other, that conform to acceptable designs and protocols and whose 
results, when considered in light of the entire body of relevant and reliable scientific 
evidence are sufficient to substantiate that the representation is true.”162
In further action, in 2010, the FTC agreed to a settlement with the Dannon Company, 
Inc. in response to an FTC complaint that charged the company with deceptive 
advertising in relation to allegedly exaggerated health benefits of its probiotic products, 
156 See Randal Shaheen & Amy Ralph Mudge, Has the FTC Changed the Game on Advertising 
Substantiation?, antitrust, Fall 2010, at 65 (quoting Novartis Corp., 127 F.T.C. 580, 725 (1999)).
157 Id. at 66.
158 Complaint at 6-7, In re Nestlé Healthcare Nutrition, Inc., No. C-4312 (FTC Jan. 18, 2011). All the 
pleadings and orders related to this case are available at http://www.ftc.gov/os/caselist/0923087/index.shtm.
159 Agreement Containing Consent Order at 4, In re Nestlé Healthcare Nutrition, FTC No. 092-3087 
(FTC May 18, 2010), http://www.ftc.gov/sites/default/files/documents/cases/2010/07/100714nestleorder.pdf. 
160 Nestle Healthcare Nutrition, Inc.; Analysis of Proposed Consent Order to Aid Public Comment, 75 
Fed. Reg. 42,752, 42,752 (July 22, 2010).
161 u.s. ftC, enforCeMent poliCy stateMent on food advertising (May 1994), available at http://
www.ftc.gov/bcp/policystmt/ad-food.shtm. 
162 Agreement Containing Consent Order, supra note 159, at 4.
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Activia yogurt and DanActive dairy drink. According to the FTC’s complaint, Dannon 
claimed in nationwide advertising campaigns that DanActive helps prevent colds and 
flu and that one daily serving of Activia relieves temporary irregularity and helps with 
“slow intestinal transit time” without sufficient evidence to back these claims. Dannon 
agreed to cease making such claims for these two products. 163 These actions on the 
part of the FTC may foreshadow FTC’s leaning toward a higher standard for making 
health claims.164 
F. Probiotic Product Labeling and Claim Recommendations
1. Labeling Recommendations
Labeling of probiotic products should include additional information than that 
currently required for other foods and dietary supplements. For example, a probiotic 
product should be labeled with the names of the genus, species, and strain of all 
the probiotic microorganisms in it, as recommended by the International Scientific 
Association for Probiotics and Prebiotics.165 Manufacturers of probiotic products 
should also be required to specify the number of live microbes of each strain that the 
products deliver through the end of their shelf life, and these numbers should reflect the 
efficacious doses used in the trials that form the basis for any claims of health benefits. 
For dietary supplements, DSHEA requires dietary supplement manufacturers to 
have substantiation of label claims and to notify the FDA, within thirty days after first 
marketing a product with a statement of nutritional support, that such a statement is 
being made. Anecdotally, some members of the WG noted that, in practice, the FDA has 
not requested this substantiation. The FDA should do so for both probiotic supplements 
and probiotic foods and require companies to make this substantiation readily available, 
for example on company websites, so that consumers and healthcare professionals can 
see for themselves the basis of the product claims.166 Finally, the FDA should adopt 
the voluntary guidelines developed by the Consumer Health Products Association for 
minimal information that should appear on the label of dietary supplements containing 
probiotics to assure safe use.167 These guidelines recommend the inclusion of the 
following information:
163 Prior to action by the FTC in this case, in 2009, the Dannon Co. settled a false advertising lawsuit 
and agreed to set up a $35-million fund to reimburse consumers who bought its Activia and DanActive 
yogurts. The class action lawsuit, filed in January 2008, alleged that Dannon made misrepresentations when 
marketing its Activia and DanActive yogurts by claiming health benefits that did not exist. As part of the 
settlement, the company, although admitting no wrongdoing, agreed to make changes to the labeling and 
advertising of Activia and DanActive. DanActive labels that said the yogurt has “a positive effect on your 
digestive tract’s immune system” were reworded to say the yogurt will “interact with your digestive tract’s 
immune system.” Nathan Olivarez-Giles, Dannon Settles False Advertising Lawsuit over Activia, DanActive 
Yogurt, l.a. tiMes, Sept. 19, 2009, http://articles.latimes.com/2009/sep/19/business/fi-yogurt-settlement19.
164 At least one commenter on the Nestlé HCN consent order characterized the requirements on the 
manufacturer as an “unusually high standard” for making claims. See Jeff Gelles, Bursting Nestlé Boost’s 
Bubble on ‘Probiotic’ Claims, pHilly.CoM (July 14, 2010), http://www.philly.com/philly/blogs/consumer/
FTC_bursts_BOOSTs_bubble_on_probiotic_claims.html.
165 int’l sCientifiC ass’n for probiotiCs and prebiotiCs (isapp), tHe p’s and Q’s of probiotiCs: 
a ConsuMer guide for Making sMart CHoiCes (2009), available at http://www.isapp.net/Portals/0/docs/
Consumer_Guidelines-probiotic.pdf.
166 See David Schardt, Recommendations for Modifications to FDA’s regulatory framework for probiotics 
(on file with the authors).
167 See essay submitted by Working Group Members June Austin (Regulatory Affairs, Procter & Gamble) 
and Nora L. Zorich (former Vice President Corporate Research and Development, Procter & Gamble) (on 
file with the investigators) referring to ConsuMer HealtH produCts ass’n, voluntary labeling guidelines 
for dietary suppleMent produCts Containing probiotiCs (adopted Nov. 17, 2011), available at http://www.
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•	 Colony Forming Units count or other appropriate measure of live bacteria at the 
time of expiration (guaranteed minimum) of the product.
•	 Storage conditions: Specific directions about the conditions under which the 
probiotic-containing product must be maintained in order to ensure viability and 
potency.168 
•	 Lot number or production code on the product containers. 
•	 A clear identification of the probiotic bacteria including the strain (unless there 
is scientific substantiation that the claimed health benefits are not strain specific) 
based on widely accepted nomenclature. If a trademarked name is used to identify 
the bacteria, the actual genus, species, and strain should also be included on the 
label.169 
•	 Contact information for the manufacturer, including an address or a telephone 
number that consumers can call if they have any questions or concerns.170 
•	 Directions for suggested usage. 
2. Probiotics Monograph
The lack of prior approval for many claims made by food and dietary supplement 
manufacturers creates an opportunity for false, misleading and unsubstantiated claims. 
A recommendation that may streamline the number of claims that a manufacturer 
can make and provide for a more efficient oversight process of claims is a probiotics 
monograph. Generally, a monograph is a kind of “recipe book” that covers acceptable 
ingredients, doses, formulations, and labeling for the product covered by the monograph. 
Monographs are updated as needed to add additional ingredients and allowable claims. 
For many years, the FDA has used a monograph for OTC drugs under which products 
such as some sunscreens, laxatives, cough-cold and other products can be sold and 
marketed without premarket approval. 
Canada currently uses a monograph to regulate certain probiotics sold in the Canadian 
market and has taken a proactive role in regulating probiotic products. Probiotic product 
classes in Canada do not correspond exactly with those in the United States; however, 
most probiotic products that would be considered dietary supplements in the United 
States are regulated as natural health products in Canada and are regulated by a probiotics 
monograph. The monograph was written based on the FAO/WHO 2006 Guidelines171 
and a targeted review of the scientific literature. All probiotic natural health products in 
Canada require pre-market assessment and licensing and must be supported by evidence 
of safety and efficacy under recommended conditions of use. Compliance with the 
monograph requirements leads to expedited review of the application for marketing 
the product. The Canadian probiotics monograph allows four specific claims for four 
specific strains of live microorganisms and limited generalized claims for combinations 
of strains that meet all additional requirements. (See Table 2 below).
chpa.org/VolCodesGuidelines.aspx.
168 ConsuMer HealtH produCts ass’n, supra note 167. Storage conditions can vary depending on strain, 
temperature, humidity, and other factors. Storage conditions should be based on stability testing under various 
conditions. Each manufacturer should establish adequate storage directions based upon product-specific 
stability and/or test data.
169 Id. This information gives consumers the knowledge and opportunity to research the strains.
170 Id. For products that lack adequate space on the label, a company should list a website where the 
consumer can obtain contact information. 
171 See food & agriC. org. of tHe u.n. & World HealtH org., supra note 7.
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tAbLe 2. probiotic product cLAimS ALLowed by  
heALth cAnAdA probioticS monogrAph
Microorganism Eligible Specific Claims
• Lactobacillus johnsonii La1 
• L. johnsonii Lj1
• L. johnsonii NCC 533
An adjunct to physician-supervised antibiotic 
therapy in patients with Helicobacter pylori 
infections 
• Lactobacillus rhamnosus GG •	 Helps to manage acute infectious 
diarrhoea.
•	 Helps to manage antibiotic-associated 
diarrhoea. 
•	 Helps to reduce the risk of antibiotic-
associated diarrhoea
• Saccharomyces boulardii Helps to reduce the risk of antibiotic-
associated diarrhoea 
Eligible General Claims
• Lactobacillus johnsonii La1
• L. johnsonii Lj1
• L. johnsonii NCC 533
• Lactobacillus rhamnosus GG
•	 Probiotic that forms part of a natural 
healthy gut flora.
•	 Provides live microorganisms that form 
part of a natural healthy gut flora.
•	 Probiotic that contributes to a natural 
healthy gut flora.
•	 Provides live microorganisms that 
contribute to a natural healthy gut flora.
• Saccharomyces boulardii
• Lactobacillus johnsonii La1
• L. johnsonii Lj1
• L. johnsonii NCC 533
• Lactobacillus rhamnosus GG
•	 Probiotic to benefit health and/or to 
confer a health benefit.
•	 Provides live microorganisms to benefit 
health and/or to confer a health benefit.
Natural health products are not limited to these claims; however, additional evidence 
supporting the product’s safety and efficacy is required for claims not specified by the 
monographs. To market a product under the monograph, manufacturers must attest to 
strain-specific evidence regarding identity, safety and efficacy. The monograph also 
requires that label quantity must be present at the product’s expiration date. As of July 
19, 2013, Health Canada had received approximately 78,500 applications for pre-market 
approval of natural health products. Specific to probiotics, at that date, 437 probiotic 
products had been licensed through the monograph process, 438 probiotic products had 
been licensed outside of the monograph process, and 48 probiotic submissions were 
in queue for evaluation. 172
Since it was developed, the Canadian probiotics monograph has received and 
responded to feedback from manufacturers, consumers and scientists. In terms of 
scientific challenges, Health Canada noted the following concerns:
•	 Inadequate lactic acid bacteria taxonomy. 
•	 Exclusion of transferrable antibiotic resistance. 
172 Michael Steller, Health Canada, Health Products and Food Branch, Natural Health Products 
Directorate (personal communication July 25, 2013). 
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•	 Scientific basis for extrapolation from strain to species. 
•	 Validated biomarkers/surrogate endpoints for gut health/immunity. 
•	 Validated methods for quality assurance.173 
To deal with these concerns, Health Canada created interim solutions to allow market 
access for products with a recognized history of safe use and long term goals that will 
require additional research and/or policy to resolve.
The probiotics monograph established in Canada could serve as a model for the U.S. 
The U.S., in fact, already has experience with monographs; a monograph for OTC drugs 
has been in place for over 40 years. When the FDCA was signed in 1938, it required 
that all new drugs obtain FDA approval of a New Drug Application (NDA) prior to 
marketing. Drugs that were already on the market, however, were “grandfathered” and 
exempt from the new drug safety requirements. When the FDCA was amended in 1962, 
through the Kefauver-Harris Amendments, it required proof of effectiveness for all new 
drugs. These amendments continued the grandfathering of pre-1938 drugs, provided that 
they were generally recognized as safe and effective (GRAS/E) for their indication.174 
In order to deal with the vast number of OTC drugs that were already on the market 
prior to the requirement that all drugs obtain an NDA, the FDA created the OTC 
monograph system to review classes of drugs and categorize them as GRAS/E after 
review by expert panels. This meant that certain classes of OTC drugs would not be 
required to obtain an NDA and could remain on the market if they conformed to the 
monograph guidelines for doses, labeling, and warnings, which are finalized in the 
Code of Federal Regulations.175
Professor James O’Reilly has recommended using the FDA’s existing OTC drug 
monograph structure as a model for the development of a monograph for probiotics.176 
His proposal is based on the concept that probiotics are a functional class of products 
that are generally recognized as safe and effective for a similar particular benefit. 
Similar to the FDA’s current OTC monographs, a probiotics monograph would include 
a list of active ingredients found to have achieved a specified benefit; levels of active 
ingredients needed to achieve the benefit; product claims that the FDA believes fairly 
communicate that benefit; mandatory warnings for this category of products; purity 
standards for active ingredients; permissible excipient and/or inactive ingredients; and 
methods and standards of testing. 
There are several benefits to using the OTC drug monograph as a model for regulating 
probiotics. The monograph mechanism has been in place for 40 years at the FDA and 
is a well-established mechanism for facilitating the marketing of certain products. 
Moreover, a probiotics monograph would generate a well-understood set of claims 
accepted by the FTC and useful in private enforcement claims. The process is open 
and familiar to industry and NGOs. A monograph would create a strong basis for active 
ingredient characterization and for use of specifications or production controls on key 
ingredients. The process could also be used as an avenue to assure safety. Furthermore, a 
173 See daniel buiJs, HoW probiotiC natural HealtH produCts are regulated in Canada (PowerPoint 
presentation, Feb. 4, 2011), available at http://www.law.umaryland.edu/programs/health/events/probiotics/
documents/Buijs_Health_Canada_Probiotics_Monograph.pdf.
174 Stan Stringer, What Has Been Happening with Over-the-Counter Drug Regulation, 53 food & drug 
l.J. 633, 633 (1998).
175 Gen. Accounting Office, HRD-82-41, FDA’s Approach to Reviewing Over-the-Counter Drugs 
Is Reasonable, but Progress Is Slow (1982), available at http://gao.gov/assets/140/137203.pdf; Food & 
Drug Admin., Regulation of Nonprescription Drug Products, available at http://www.fda.gov/downloads/
AboutFDA/CentersOffices/CDER/UCM148055.pdf (PowerPoint presentation) (last visited May 7, 2014). 
176 James O’Reilly, “Yes, it walks like a duck . . .” Changing the Culture of Those Who Market Probiotic 
Cultures (on file with the authors).
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monograph would likely meet with success in court challenges because of the history of 
successfully overcoming past criticisms of the OTC drug monographs. 177 It would also 
provide assurance to the FDA and FTC that a product approved under the monograph 
has met a certain standard, and the FTC would likely defer to it.178
A monograph could address foods or dietary supplements that want to make health 
claims by indicating which claims could be made about which ingredients, such as those 
permitted in Canada. 179 A monograph could also address characterization issues specific 
to probiotics. Finally, although Canada’s monograph requires pre-market approval, 
the FDA OTC monograph does not. Borrowing from both models would allow for a 
streamlined process that could reduce the number of unsubstantiated probiotic claims 
and allow marketing without prior individual product approval.180 
viii. concLuSion
In establishing a regulatory framework for probiotics in the United States and other 
countries, policy makers should be guided by certain foundational principles. These 
include proportionality to risk, universal quality guidelines, and flexibility.181 
Regulatory burden should be proportional to risk. This principle is already reflected 
in both Canada and the United States in the distinction between the regulation of food 
and drugs. In the context of probiotic products, the fact that products identified as 
“probiotic” can have very different risk profiles that are affected not just by the intrinsic 
risk of the strain itself, but also by the intended application, needs to be recognized and 
communicated to regulators, researchers, industry, and most importantly, to consumers. 
The use of the word “probiotic” to describe these types of products should be further 
qualified in some way (i.e., general probiotic vs. clinical probiotic), and the qualifications 
clearly defined and enforced. Because the intended application needs to be considered 
during risk classification, there should be a mechanism for a strain to be regulated 
simultaneously at different risk levels for different applications. There should be a 
publicly available mechanism through which consumers can obtain more information 
on the underlying evidence supporting a particular product. 
A significant determinant of the risk of probiotic products, including the risk of failed 
efficacy, is quality control during manufacturing. This risk is not always easy to assess 
by researchers, regulators or consumers. The manufacture of probiotic products that 
are pure and sufficiently stable for retail distribution is technically challenging. Both 
Canada and the United States have pre-market approval systems that are appropriate 
for assessing the quality control systems of the highest risk products, biologics and 
live biotherapeutics, respectively. However, this level of rigorous pre-market review 
177 Id.
178 Id. Another potential benefit of a probiotic monograph is that if user fees were an option for companies 
seeking approval under the monograph, the fees could be used to enhance the FDA’s enforcement efforts. 
Finally, depending on how it was designed, a probiotic monograph could probably be established without 
requiring statutory approval. Id.
179 See Table 2, supra. Any claim that would be considered a drug claim, however, would likely require 
statutory approval.
180 In terms of process, before creating a monograph for probiotics, the FDA would have to decide the 
focus of the monograph—for example, the probiotic strain; a bodily function (i.e., gut health, vaginal health, 
skin health, etc.); specific product types (e.g., skin creams); or a class of products (e.g., health promotion 
products). Ideally, a monograph would be created with a focus that was sufficiently flexible to incorporate 
new products or strains as they were developed. 
181 See Daniel Buijs, Recommendations for Establishing a Regulatory Framework for Probiotics 
(on file with the investigators). The description of these principles is taken in large part from Mr. Buijs’ 
recommendations.
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is not appropriate or sustainable for lower-risk products. An adequate level of control 
and enforcement could be achieved for lower-risk products through the publication of 
universal quality standards. 
The last and most important principle that should be considered in the regulation 
of probiotics is flexibility. The science and technology surrounding these products are 
progressing rapidly. In addition to being able to simultaneously accommodate products of 
different risk profiles, the regulatory framework for probiotics should take into account 
the eventuality that the level of scientific certainty associated with these products, and 
the methods used to study them, will change over time. This new knowledge will result 
in some products becoming lower-risk over time, but may also identify new hazards 
that were previously unknown or underappreciated. The regulatory regime must be 
nimble enough to respond.
 
